BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
Number Citing Articles
1 Yang WX, Pan YY, You CG. CDK1, CCNB1, CDC20, BUB1, MAD2L1, MCM3, BUB1B, MCM2, and RFC4 May Be Potential Therapeutic Targets for Hepatocellular Carcinoma Using Integrated Bioinformatic Analysis. Biomed Res Int 2019;2019:1245072. [PMID: 31737652 DOI: 10.1155/2019/1245072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
2 Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2021:S1590-8658(21)00766-0. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Reference Citation Analysis]
3 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]
4 Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS. Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. J Hepatocell Carcinoma 2021;8:657-70. [PMID: 34235104 DOI: 10.2147/JHC.S316223] [Reference Citation Analysis]
5 Özdemir F, Baskiran A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 2020;51:1127-32. [DOI: 10.1007/s12029-020-00486-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Abdelaziz AO, Nabil MM, Omran DA, Abdelmaksoud AH, Asem N, Shousha HI, Elbaz TM, Leithy R. Hepatocellular Carcinoma Multidisciplinary Clinic-Cairo University (HMC-CU) score: A new simple score for diagnosis of HCC. Arab J Gastroenterol 2020;21:102-5. [PMID: 32439235 DOI: 10.1016/j.ajg.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang M, Xiong Z. The Mutation and Expression Level of LRP1B are Associated with Immune Infiltration and Prognosis in Hepatocellular Carcinoma. Int J Gen Med 2021;14:6343-58. [PMID: 34629898 DOI: 10.2147/IJGM.S333390] [Reference Citation Analysis]
8 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Fan PL, Xia HS, Ding H, Dong Y, Chen LL, Wang WP. Characterization of Early Hepatocellular Carcinoma and High-Grade Dysplastic Nodules on Contrast-Enhanced Ultrasound: Correlation With Histopathologic Findings. J Ultrasound Med 2020;39:1799-808. [PMID: 32378794 DOI: 10.1002/jum.15288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kang H, Lee JM, Yoon JH, Lee K, Kim H, Han JK. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane for the Diagnosis of Hepatocellular Carcinoma in Individuals with High Risk. Radiology 2020;297:108-16. [DOI: 10.1148/radiol.2020200115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Yan H, Gao X, Zhang Y, Chang W, Li J, Li X, Du Q, Li C. Imaging Tiny Hepatic Tumor Xenografts via Endoglin-Targeted Paramagnetic/Optical Nanoprobe. ACS Appl Mater Interfaces. 2018;10:17047-17057. [PMID: 29708329 DOI: 10.1021/acsami.8b02648] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
12 Li JL, Ye WT, Yan LF, Liu ZY, Cao XM, Liang CH. Influence of tube voltage, tube current and newer iterative reconstruction algorithms in CT perfusion imaging in rabbit liver VX2 tumors. Diagn Interv Radiol 2020;26:264-70. [PMID: 32490833 DOI: 10.5152/dir.2019.19147] [Reference Citation Analysis]
13 Ren X, Ji Y, Jiang X, Qi X. Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus. Biosci Rep 2018;38:BSR20181423. [PMID: 30355653 DOI: 10.1042/BSR20181423] [Reference Citation Analysis]
14 Park HJ, Seo KI, Kim SJ, Lee SU, Yun BC, Han BH, Shin DH, Choi YI, Moon HH. Effectiveness of Albumin-bilirubin Score as a Predictor of Post-hepatectomy Liver Failure in Patients with Hepatocellular Carcinoma. Korean J Gastroenterol 2021;77:115-22. [PMID: 33658474 DOI: 10.4166/kjg.2020.148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Abouzied MM, Fathala A, AlMuhaideb A, Almanea H, Al-Sugair AS, AlSkaff R, Al-Qahtani MH. Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature. Radiol Case Rep 2021;16:550-4. [PMID: 33384755 DOI: 10.1016/j.radcr.2020.12.047] [Reference Citation Analysis]
16 Li C, Lu X, Xiao J, Chan CWH. 'We can bear it!' Unpacking barriers to hepatocellular carcinoma screening among patients with hepatitis B: A qualitative study. J Clin Nurs 2021. [PMID: 34816510 DOI: 10.1111/jocn.16140] [Reference Citation Analysis]
17 Liu Y, Yang Y, Jiang L, Xu H, Wei J. High Expression Levels of SLC38A1 Are Correlated with Poor Prognosis and Defective Immune Infiltration in Hepatocellular Carcinoma. J Oncol 2021;2021:5680968. [PMID: 34697542 DOI: 10.1155/2021/5680968] [Reference Citation Analysis]
18 Hack SP, Spahn J, Chen M, Cheng A, Kaseb A, Kudo M, Lee HC, Yopp A, Chow P, Qin S. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology 2020;16:975-89. [DOI: 10.2217/fon-2020-0162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
19 Bae JS, Lee DH, Lee SM, Suh KS, Lee KW, Yi NJ, Lee KB, Kim H, Han JK. Performance of LI-RADS Version 2018 on CT for Determining Eligibility for Liver Transplantation According to Milan Criteria in Patients at High Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35138137 DOI: 10.2214/AJR.21.27186] [Reference Citation Analysis]
20 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
21 You Y, Long Y, Yan R, Luo L, Zhang M, Li L, Zeng Q, Li K, Zheng R, Xu E. Improving Ablation Safety for Hepatocellular Carcinoma Proximal to the Hilar Bile Ducts by Ultrasound-MR Fusion Imaging: A Preliminary Comparative Study. Front Oncol 2021;11:570312. [PMID: 33732639 DOI: 10.3389/fonc.2021.570312] [Reference Citation Analysis]
22 Chen X, Lai L, Ye J, Li L. Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:740762. [PMID: 34868936 DOI: 10.3389/fonc.2021.740762] [Reference Citation Analysis]
23 Nguyen-Dinh SH, Do A, Pham TND, Dao DY, Nguy TN, Chen Jr MS. High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. World J Hepatol 2018; 10(1): 116-123 [PMID: 29399285 DOI: 10.4254/wjh.v10.i1.116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
24 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
25 Liu Z, Fu Z, Li G, Lin D. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report. Onco Targets Ther 2020;13:10267-73. [PMID: 33116607 DOI: 10.2147/OTT.S261521] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wang Y, Wang M, Li H, Chen K, Zeng H, Bi X, Zhu Z, Jiao Y, Wang Y, Zhu J, Zhao H, Liu X, Dai C, Fan C, Zhao C, Guo D, Zhao H, Zhou J, Wang D, Wu Z, Zhao X, Cui W, Zhang X, Cai J, Chen W, Qu C. A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers. Chin J Cancer Res 2021;33:352-63. [PMID: 34321832 DOI: 10.21147/j.issn.1000-9604.2021.03.07] [Reference Citation Analysis]
27 Su TH, Liao SH, Hong CM, Liu CJ, Tseng TC, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL, Adhoute X, Bourlière M, Kao JH. NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging. J Gastroenterol Hepatol 2019;34:2179-86. [PMID: 31062879 DOI: 10.1111/jgh.14705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Shibuya K, Ohno T, Terashima K, Toyama S, Yasuda S, Tsuji H, Okimoto T, Shioyama Y, Nemoto K, Kamada T, Nakano T; Japan Carbon Ion Radiotherapy Study Group. Short-course carbon-ion radiotherapy for hepatocellular carcinoma: A multi-institutional retrospective study. Liver Int. 2018;38:2239-2247. [PMID: 30240527 DOI: 10.1111/liv.13969] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
30 Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889-919. [PMID: 33006093 DOI: 10.1007/s12072-020-10094-2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 67] [Article Influence: 30.5] [Reference Citation Analysis]
31 Xu X, Zhang HL, Liu QP, Sun SW, Zhang J, Zhu FP, Yang G, Yan X, Zhang YD, Liu XS. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019;70:1133-1144. [PMID: 30876945 DOI: 10.1016/j.jhep.2019.02.023] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 40.3] [Reference Citation Analysis]
32 Arellano RS. What's New in Percutaneous Ablative Strategies for Hepatocellular Carcinoma and Colorectal Hepatic Metastases? 2020 Update. Curr Oncol Rep 2020;22:105. [PMID: 32725433 DOI: 10.1007/s11912-020-00967-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Marks RM, Masch WR, Chernyak V. LI-RADS: Past, Present, and Future, From the AJR Special Series on Radiology Reporting and Data Systems. American Journal of Roentgenology 2021;216:295-304. [DOI: 10.2214/ajr.20.24272] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Fukushima T, Morimoto M, Kobayashi S, Ueno M, Sano Y, Kawano K, Asama H, Nagashima S, Maeda S. Repeated transarterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres vs. conventional transarterial chemoembolization for hepatocellular carcinoma. Mol Clin Oncol 2021;14:119. [PMID: 33903825 DOI: 10.3892/mco.2021.2281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, Chen T, Qu C. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. Int J Infect Dis 2019;78:130-9. [PMID: 30466898 DOI: 10.1016/j.ijid.2018.08.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Varol Fİ. Pediatric Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1169-75. [PMID: 32856229 DOI: 10.1007/s12029-020-00494-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Wang D, Xu Y, Goldstein JB, Ye K, Hu X, Xiao L, Li L, Chang L, Guan Y, Long G, He Q, Yi X, Zhang J, Wang Z, Xia X, Zhou L. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int 2020;40:1997-2007. [PMID: 32279416 DOI: 10.1111/liv.14463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Chen P, Chiu N, Su C, Huang Y, Hou M, Lin H, Wu J. Albumin-bilirubin grade may determine the outcomes of patients with very early stage hepatocellular carcinoma after radiofrequency ablation therapy. Journal of the Chinese Medical Association 2019;82:2-10. [DOI: 10.1097/jcma.0000000000000001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
40 Lin CC, Lui KW, Chen WT, Hsieh YC, Cheng YT, Teng W, Lin SM. Switching monopolar radiofrequency ablation improves long-term outcomes of medium-sized hepatocellular carcinoma. Eur Radiol 2021. [PMID: 33895858 DOI: 10.1007/s00330-021-07729-9] [Reference Citation Analysis]
41 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
42 Hyun D, Cho SK, Shin SW, Park KB, Park HS, Choo SW, Do YS. Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:587-96. [PMID: 31912214 DOI: 10.1007/s00270-019-02405-4] [Reference Citation Analysis]
43 Hendi M, Mou Y, Lv J, Zhang B, Cai X. Hepatic Arterial Infusion Chemotherapy Is a Feasible Treatment Option for Hepatocellular Carcinoma: A New Update. Gastrointest Tumors 2021;8:145-52. [PMID: 34722467 DOI: 10.1159/000516405] [Reference Citation Analysis]
44 Ma C, Ma Y, Lu S, Li D, Wang Y, Xu Y, Zhang T, Du Y, Wang L. Clinical Study on Effect of Solution Focused Approach on the Complications, Pain, Sleep, and Quality of Life in Patients with Hepatocellular Carcinoma Undergoing TACE. Evid Based Complement Alternat Med 2021;2021:5068228. [PMID: 34567212 DOI: 10.1155/2021/5068228] [Reference Citation Analysis]
45 Wei J, Liu Y, Zhao C. Integrated Analysis of FAM57A Expression and Its Potential Roles in Hepatocellular Carcinoma. Front Oncol 2021;11:719973. [PMID: 34790567 DOI: 10.3389/fonc.2021.719973] [Reference Citation Analysis]
46 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
47 Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR; Expert Panel on Gastrointestinal Imaging. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol 2020;17:S70-80. [PMID: 32370979 DOI: 10.1016/j.jacr.2020.01.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Gatti P, Giorgio A, Ciracì E, Roberto I, Anglani A, Sergio S, Rizzello F, Giorgio V, Semeraro S. Hepatocellular carcinoma tumor thrombus entering the inferior vena cava treated with percutaneous RF ablation: a case report. J Ultrasound 2019;22:363-70. [PMID: 30864004 DOI: 10.1007/s40477-019-00361-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
49 Xia X, Zhang H, Xia P, Zhu Y, Liu J, Xu K, Yuan Y. Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma. Front Oncol 2021;11:733595. [PMID: 34527595 DOI: 10.3389/fonc.2021.733595] [Reference Citation Analysis]
50 Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH;  REAL-C Investigators. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatol Int. 2019;13:587-598. [PMID: 31463665 DOI: 10.1007/s12072-019-09974-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
51 Yip TC, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW, Wong GL. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology 2018;113:1629-38. [DOI: 10.1038/s41395-018-0247-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
52 Lin ZZ, Bo N, Fan YC, Wu YT, Yao HL, Chen S, Yu HF, Jiang LH. Xanthomicrol suppresses human hepatocellular carcinoma cells migration and invasion ability via Μu-opioid receptor. J Pharm Pharmacol 2021:rgab104. [PMID: 34355768 DOI: 10.1093/jpp/rgab104] [Reference Citation Analysis]
53 Shuai Y, Ma Z, Lu J, Feng J. LncRNA SNHG15: A new budding star in human cancers. Cell Prolif. 2020;53:e12716. [PMID: 31774607 DOI: 10.1111/cpr.12716] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
54 Rastogi A. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 4000-4013 [PMID: 30254404 DOI: 10.3748/wjg.v24.i35.4000] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
55 Cheuk-fung Yip T, Wai-sun Wong V, Lik-yuen Chan H, Tse Y, Pik-shan Kong A, Long-yan Lam K, Chung-yan Lui G, Lai-hung Wong G. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology 2018;16:765-773.e2. [DOI: 10.1016/j.cgh.2017.12.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
56 Lee CM, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int 2021;15:676-84. [PMID: 33956288 DOI: 10.1007/s12072-021-10190-x] [Reference Citation Analysis]
57 Huang X, Lee F, Teng Y, Lingam CB, Chen Z, Sun M, Song Z, Balachander GM, Leo HL, Guo Q, Shah I, Yu H. Sequential drug delivery for liver diseases. Adv Drug Deliv Rev 2019;149-150:72-84. [PMID: 31734169 DOI: 10.1016/j.addr.2019.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
58 Zhang YX, Zhang XH, Yu XL, Han ZY, Yu J, Liu FY, Cheng ZG, Liang P. Prognosis of microwave ablation for hepatocellular carcinoma: does age make a difference? Int J Hyperthermia 2020;37:688-95. [PMID: 32558602 DOI: 10.1080/02656736.2020.1778198] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61. [PMID: 31541423 DOI: 10.1007/s12072-019-09988-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
60 Chen J, Xia C, Duan T, Cao L, Jiang H, Liu X, Zhang Z, Ye Z, Wu Z, Gao R, Shi Y, Song B. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021. [PMID: 33856520 DOI: 10.1007/s00330-021-07898-7] [Reference Citation Analysis]
61 Chen CZ, Zhong JH, Qi YP, Zhang J, Huang T, Ma L, Li LQ, Peng T, Xiang BD. Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients. Biosci Rep 2021;41:BSR20201928. [PMID: 33835138 DOI: 10.1042/BSR20201928] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:517-523. [PMID: 31524775 DOI: 10.1097/MEG.0000000000001528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Wang J, Wang J, Wang J, Qian Z, Xu W, Hang X. Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. J Int Med Res 2021;49:300060521994406. [PMID: 33596694 DOI: 10.1177/0300060521994406] [Reference Citation Analysis]
64 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
65 Yen YH, Cheng YF, Wang JH, Lin CC, Chen YY, Yong CC, Liu YW, Cheng JY, Chen CH, Hu TH. Real world clinical practice in treating advanced hepatocellular carcinoma: When East meets West. PLoS One 2020;15:e0230005. [PMID: 32163475 DOI: 10.1371/journal.pone.0230005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
66 Lin WC, Lin YS, Chang CW, Chang CW, Wang TE, Wang HY, Chen MJ. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. PLoS One. 2020;15:e0233212. [PMID: 32442193 DOI: 10.1371/journal.pone.0233212] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
68 Chinnaratha MA, Campbell K, Mathias R, McCormick RJ, Woodman RJ, Wigg AJ. Improved Survival of Hepatocellular Carcinoma Patients Diagnosed with a Dedicated Screening Programme-a Propensity Score Adjusted Analysis. J Gastrointest Cancer 2019;50:888-93. [PMID: 30345486 DOI: 10.1007/s12029-018-0171-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Dai J, Zhao J, Du Y, Zhuang L, McNeil EB, Chongsuvivatwong V. Adherence to Hepatocellular Carcinoma Surveillance and Perceived Barriers Among High-Risk Chronic Liver Disease Patients in Yunnan, China. Cancer Manag Res 2020;12:6209-20. [PMID: 32884337 DOI: 10.2147/CMAR.S259195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
71 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D; Cochrane Hepato-Biliary Group. Computed tomography for the diagnosis of hepatocellular carcinoma in chronic advanced liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013362] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
72 Mei J, Lin WP, Shi F, Wei W, Liang JB, Shi M, Zheng L, Li SH, Guo RP. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy. Eur J Radiol 2021;142:109890. [PMID: 34375811 DOI: 10.1016/j.ejrad.2021.109890] [Reference Citation Analysis]
73 Nie G, Peng D, Li B, Lu J, Xiong X. Diagnostic Accuracy of Circular RNAs in Different Types of Samples for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:794105. [PMID: 34992634 DOI: 10.3389/fgene.2021.794105] [Reference Citation Analysis]
74 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Ogawa M, Matsuoka S, Karp SJ, Moriyama M. Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives. Int J Mol Sci 2020;21:E4906. [PMID: 32664553 DOI: 10.3390/ijms21144906] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Yu MQ, An TZ, Li JX, Chang DH, Zhang ZS, Xiao YD. Integrated Liver Inflammatory Score Predicts the Therapeutic Outcome of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:1194-202. [PMID: 33819601 DOI: 10.1016/j.jvir.2021.03.540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Li X, Wu YS, Chen D, Lin H. Laparoscopic hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2019;11:5711-24. [PMID: 31417314 DOI: 10.2147/CMAR.S189777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e28545. [PMID: 35089192 DOI: 10.1097/MD.0000000000028545] [Reference Citation Analysis]
78 Wang Y, Yang L, Chen T, Liu X, Guo Y, Zhu Q, Tong X, Yang W, Xu Q, Huang D, Tu K. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18:28. [PMID: 30782188 DOI: 10.1186/s12943-019-0957-7] [Cited by in Crossref: 144] [Cited by in F6Publishing: 164] [Article Influence: 48.0] [Reference Citation Analysis]
79 Hsieh Y, Limquiaco JL, Lin C, Chen W, Lin S. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol 2019;44:1141-51. [DOI: 10.1007/s00261-018-1831-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
80 Dawuti W, Zheng X, Liu H, Zhao H, Dou J, Sun L, Chu J, Lin R, Lü G. Urine surface-enhanced Raman spectroscopy combined with SVM algorithm for rapid diagnosis of liver cirrhosis and hepatocellular carcinoma. Photodiagnosis Photodyn Ther 2022;:102811. [PMID: 35304310 DOI: 10.1016/j.pdpdt.2022.102811] [Reference Citation Analysis]
81 Wan Y, Zheng Z, Liu R, Zhu Z, Zhou H, Zhang X, Boumaraf S. A Multi-Scale and Multi-Level Fusion Approach for Deep Learning-Based Liver Lesion Diagnosis in Magnetic Resonance Images with Visual Explanation. Life (Basel) 2021;11:582. [PMID: 34207262 DOI: 10.3390/life11060582] [Reference Citation Analysis]
82 Ricke J, Steffen IG, Bargellini I, Berg T, Bilbao Jaureguizar JI, Gebauer B, Iezzi R, Loewe C, Karçaaltincaba M, Pech M, Sengel C, van Delden O, Vandecaveye V, Zech CJ, Seidensticker M. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep 2020;2:100173. [PMID: 33103093 DOI: 10.1016/j.jhepr.2020.100173] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
83 Natu A, Singh A, Gupta S. Hepatocellular carcinoma: Understanding molecular mechanisms for defining potential clinical modalities. World J Hepatol 2021; 13(11): 1568-1583 [PMID: 34904030 DOI: 10.4254/wjh.v13.i11.1568] [Reference Citation Analysis]
84 Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatology Research 2021;51:461-71. [DOI: 10.1111/hepr.13595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
85 Cachay ER, Hadigan C, Mathews WC. Clinical guidelines for screening of liver cirrhosis complications remain, and clinical judgement must prevail. AIDS 2021;35:2211-3. [PMID: 34602589 DOI: 10.1097/QAD.0000000000003022] [Reference Citation Analysis]
86 Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, Lubel JS, Kronborg I, Arachchi N, Ryan M, Kemp WW, Knight V, Sundararajan V, Desmond P, Thompson AJ, Bell SJ. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust 2018;209:348-54. [PMID: 30309301 DOI: 10.5694/mja18.00373] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
87 Solaini L, Cucchetti A, Piccino M, Gardini A, La Barba G, Serenari M, Cescon M, Ercolani G. Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma. Future Oncol 2019;15:439-49. [PMID: 30620230 DOI: 10.2217/fon-2018-0269] [Reference Citation Analysis]
88 Del Poggio P, Mazzoleni M, Lazzaroni S, D'Alessio A. Surveillance for hepatocellular carcinoma at the community level: Easier said than done. World J Gastroenterol 2021; 27(37): 6180-6190 [PMID: 34712026 DOI: 10.3748/wjg.v27.i37.6180] [Reference Citation Analysis]
89 Lee MH, Ahn SH, Chan HLY, Choudhry A, Alvani Gani R, Mohamed R, Ong JP, Shukla A, Tan CK, Tanwandee T, Thuy PTT, Neo BL, Tsang V, Youn J, Singh S. Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large-scale Asian study. J Viral Hepat 2021. [PMID: 34817896 DOI: 10.1111/jvh.13636] [Reference Citation Analysis]
90 Shindoh J, Kawamura Y, Kobayashi Y, Akuta N, Kobayashi M, Suzuki Y, Ikeda K, Hashimoto M. Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes after Resection of Hepatocellular Carcinoma. J Gastrointest Surg 2020;24:50-7. [PMID: 31190124 DOI: 10.1007/s11605-019-04277-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
91 Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, Brade A, Dinniwell R, Wong RKS, Cho C, Kim TK, Sapisochin G, Dawson LA. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120-126. [PMID: 33285195 DOI: 10.1016/j.radonc.2020.11.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
92 Zhai W, Lai H, Kaya NA, Chen J, Yang H, Lu B, Lim JQ, Ma S, Chew SC, Chua KP, Alvarez JJS, Chen PJ, Chang MM, Wu L, Goh BKP, Chung AY, Chan CY, Cheow PC, Lee SY, Kam JH, Kow AW, Ganpathi IS, Chanwat R, Thammasiri J, Yoong BK, Ong DB, de Villa VH, Dela Cruz RD, Loh TJ, Wan WK, Zeng Z, Skanderup AJ, Pang YH, Madhavan K, Lim TK, Bonney G, Leow WQ, Chew V, Dan YY, Tam WL, Toh HC, Foo RS, Chow PK. Dynamic phenotypic heterogeneity and the evolution of multiple RNA subtypes in hepatocellular carcinoma: the PLANET study. Natl Sci Rev 2022;9:nwab192. [PMID: 35382356 DOI: 10.1093/nsr/nwab192] [Reference Citation Analysis]
93 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
94 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
95 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
96 Chen Y, Zhang J, Liu J, Wang J, Shi C, Lu L, Cheng X, Niu G, Zhang S, Cui D. The Expression and Clinical Significance of PCNAP1 in Hepatocellular Carcinoma Patients. Journal of Immunology Research 2022;2022:1-7. [DOI: 10.1155/2022/1817694] [Reference Citation Analysis]
97 Chen CP. Role of External Beam Radiotherapy in Hepatocellular Carcinoma. Clin Liver Dis 2020;24:701-17. [PMID: 33012454 DOI: 10.1016/j.cld.2020.07.006] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Sangiovanni A, Colombo M. Surveillance for hepatocellular carcinoma in patients with advanced liver fibrosis. Saudi J Gastroenterol 2021;27:64-72. [PMID: 33723094 DOI: 10.4103/sjg.sjg_636_20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Mähringer-Kunz A, Steinle V, Kloeckner R, Schotten S, Hahn F, Schmidtmann I, Hinrichs JB, Düber C, Galle PR, Lang H, Weinmann A. The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. PLoS One 2021;16:e0249426. [PMID: 33961627 DOI: 10.1371/journal.pone.0249426] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, Kim KW, Lee SS. Characterizing Computed Tomography-Detected Arterial Hyperenhancing-Only Lesions in Patients at Risk of Hepatocellular Carcinoma: Can Non-Contrast Magnetic Resonance Imaging Be Used for Sequential Imaging? Korean J Radiol 2020;21:280-9. [PMID: 32090520 DOI: 10.3348/kjr.2019.0447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol 2021;:JCO2100608. [PMID: 34648352 DOI: 10.1200/JCO.21.00608] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
102 Shin J, Yu JH, Jin YJ, Suh YJ, Kim DH, Byun S, Lee JW. Effective therapeutic options for elderly patients with hepatocellular carcinoma: A nationwide cohort study. Medicine (Baltimore) 2019;98:e16150. [PMID: 31348228 DOI: 10.1097/MD.0000000000016150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Hallemeier CL, Apisarnthanarax S, Dawson LA. BCLC 2022 update: Important advances, but missing external beam radiotherapy. J Hepatol 2022:S0168-8278(21)02306-0. [PMID: 34990748 DOI: 10.1016/j.jhep.2021.12.029] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Chang YS, Lee YT, Yen JC, Chang YC, Lin LL, Chan WL, Chang WC, Lin SY, Chang JG. Long Noncoding RNA NTT Context-Dependently Regulates MYB by Interacting With Activated Complex in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:592045. [PMID: 34616668 DOI: 10.3389/fonc.2021.592045] [Reference Citation Analysis]
105 An C, Kim DY, Choi JY, Han KH, Roh YH, Kim MJ. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915. [PMID: 30249190 DOI: 10.1186/s12885-018-4827-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
106 Xie Q, Liu H, Guo Z, Wu Y, He G, Cai L, Pan M, Fu S. Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Front Mol Biosci 2022;8:810251. [DOI: 10.3389/fmolb.2021.810251] [Reference Citation Analysis]
107 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
108 Wang X, Yuan Y, Wang J, Liu Z, Chen M, Zhou Q, Zhou Z. Preoperative Versus Postoperative Transarterial Chemoembolization on Prognosis of Large Hepatocellular Carcinoma. J Cancer 2021;12:6231-41. [PMID: 34539896 DOI: 10.7150/jca.55806] [Reference Citation Analysis]
109 Reimer RP, Hokamp NG, Niehoff J, Zopfs D, Lennartz S, Heidar M, Wahba R, Stippel D, Maintz D, Dos Santos DP, Wybranski C. Value of spectral detector computed tomography for the early assessment of technique efficacy after microwave ablation of hepatocellular carcinoma. PLoS One 2021;16:e0252678. [PMID: 34129650 DOI: 10.1371/journal.pone.0252678] [Reference Citation Analysis]
110 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
111 Sano T, Kawaguchi T, Ide T, Amano K, Kuwahara R, Arinaga-Hino T, Torimura T. Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B. Life (Basel) 2021;11:263. [PMID: 33806752 DOI: 10.3390/life11030263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Chen ZH, Wang K, Zhang XP, Feng JK, Chai ZT, Guo WX, Shi J, Wu MC, Lau WY, Cheng SQ. A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus. Hepatobiliary Surg Nutr. 2020;9:717-728. [PMID: 33299827 DOI: 10.21037/hbsn.2019.10.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Chon HY, Lee JS, Lee HW, Chun HS, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Impact of antiviral therapy on risk prediction model for hepatocellular carcinoma development in patients with chronic hepatitis B. Hepatology Research 2021;51:406-16. [DOI: 10.1111/hepr.13600] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Chen LC, Lin HY, Lee MS, Chiou WY, Huang LW, Chew CH, Hsu FC, Hung SK. Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. Tzu Chi Med J 2021;33:380-7. [PMID: 34760635 DOI: 10.4103/tcmj.tcmj_247_20] [Reference Citation Analysis]
116 Cannella R, Vernuccio F, Antonucci M, Gagliano DS, Matteini F, Midiri M, Brancatelli G. LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations? Eur Radiol 2021. [PMID: 34545444 DOI: 10.1007/s00330-021-08267-0] [Reference Citation Analysis]
117 Azer SA. Deep learning with convolutional neural networks for identification of liver masses and hepatocellular carcinoma: A systematic review. World J Gastrointest Oncol 2019; 11(12): 1218-1230 [PMID: 31908726 DOI: 10.4251/wjgo.v11.i12.1218] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 16] [Article Influence: 8.7] [Reference Citation Analysis]
118 Ikeda K. Recent advances in medical management of hepatocellular carcinoma. Hepatol Res. 2019;49:14-32. [PMID: 30308081 DOI: 10.1111/hepr.13259] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
119 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
120 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
121 Wang J, Li Y, Zhang C, Chen X, Zhu L, Luo T. A hypoxia-linked gene signature for prognosis prediction and evaluating the immune microenvironment in patients with hepatocellular carcinoma. Transl Cancer Res 2021;10:3979-92. [PMID: 35116696 DOI: 10.21037/tcr-21-741] [Reference Citation Analysis]
122 Cheung TT, Ma KW, She WH, Dai WC, Tsang SHY, Chan ACY, Lo CM. Pure laparoscopic versus open major hepatectomy for hepatocellular carcinoma with liver F4 cirrhosis without routine Pringle maneuver - A propensity analysis in a single center. Surg Oncol 2020;35:315-20. [PMID: 32977103 DOI: 10.1016/j.suronc.2020.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
123 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
124 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, Sirlin CB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021;31:5615-28. [PMID: 33523304 DOI: 10.1007/s00330-020-07637-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Chang M, Fischler B, Blauvelt B, Ciocca M, Dhawan A, Ekong U, Ni Y, Porta G, Sibal A, Dagostino D, Wirth S, Morhan N, Schwarz KB. Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies. Journal of Pediatric Gastroenterology & Nutrition 2019;69:648-54. [DOI: 10.1097/mpg.0000000000002483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Combined albumin-bilirubin grade and Mac-2 binding protein glycosylation isomer as a useful predictor in compensated liver cirrhosis. Medicine (Baltimore) 2019;98:e18366. [PMID: 31852142 DOI: 10.1097/MD.0000000000018366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Zheng K, Liao A, Yan L, Yang J, Wen T, Wang W, Li B, Wu H, Jiang L. Hepatic Resection Combined with Intraoperative Radiofrequency Ablation Versus Hepatic Resection Alone for Selected Patients with Moderately Advanced Multifocal Hepatocellular Carcinomas. Ann Surg Oncol 2022. [PMID: 35441310 DOI: 10.1245/s10434-022-11757-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
128 Cai X, Chen Z, Chen J, Ma X, Bai M, Wang T, Chen X, Wu D, Wei L, Li X, Lin Q, Wen J, Ruan D, Lin Z, Dong M, Wu X. Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. J Cancer 2018;9:189-97. [PMID: 29290785 DOI: 10.7150/jca.21799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
129 Su TH, Hsu SJ, Kao JH. Paradigm shift in the treatment options of hepatocellular carcinoma. Liver Int 2021. [PMID: 34515412 DOI: 10.1111/liv.15052] [Reference Citation Analysis]
130 Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. J Hep Reports. 2019;1:114-119. [PMID: 32039359 DOI: 10.1016/j.jhepr.2019.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
131 Kokudo T, Kokudo N. What liver surgeons have achieved in the recent decade for patients with hepatocellular carcinoma? Glob Health Med 2020;2:265-8. [PMID: 33330819 DOI: 10.35772/ghm.2020.01086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
132 Strobel D. Using contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma - what we have and have not achieved. Ultraschall Med 2021;42:120-4. [PMID: 33845488 DOI: 10.1055/a-1347-1388] [Reference Citation Analysis]
133 Ng KKC, Cheng NMY, Huang J, Liao M, Chong CCN, Lee KF, Wong J, Cheung SYS, Lok HT, Fung AKY, Wong GLH, Wong VWS, Lai PBS. Development and validation of a novel nomogram predicting 10-year actual survival after curative hepatectomy for hepatocellular carcinoma. Surgeon 2021:S1479-666X(20)30186-4. [PMID: 33423927 DOI: 10.1016/j.surge.2020.11.013] [Reference Citation Analysis]
134 Dalal K, Dalal B, Bhatia S, Shukla A, Shankarkumar A. Analysis of serum Haptoglobin using glycoproteomics and lectin immunoassay in liver diseases in Hepatitis B virus infection. Clin Chim Acta 2019;495:309-17. [PMID: 31014754 DOI: 10.1016/j.cca.2019.04.072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
135 Tan Z, Teoh WC, Wong KM, Wansaicheong GK, Sandrasegaran K. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clinical Imaging 2020;62:63-8. [DOI: 10.1016/j.clinimag.2020.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
136 Mojtahed A, Núñez L, Connell J, Fichera A, Nicholls R, Barone A, Marieiro M, Puddu A, Arya Z, Ferreira C, Ridgway G, Kelly M, Lamb HJ, Caseiro-Alves F, Brady JM, Banerjee R. Repeatability and reproducibility of deep-learning-based liver volume and Couinaud segment volume measurement tool. Abdom Radiol (NY) 2021. [PMID: 34605963 DOI: 10.1007/s00261-021-03262-x] [Reference Citation Analysis]
137 Wang X, Sun L, Zhang H, Wei L, Qu W, Zeng Z, Liu Y, Zhu Z. Microfluidic chip combined with magnetic-activated cell sorting technology for tumor antigen-independent sorting of circulating hepatocellular carcinoma cells. PeerJ 2019;7:e6681. [PMID: 30972256 DOI: 10.7717/peerj.6681] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
138 Thuluvath PJ, To C, Amjad W. Role of Locoregional Therapies in Patients With Hepatocellular Cancer Awaiting Liver Transplantation. Am J Gastroenterol 2021;116:57-67. [PMID: 33110015 DOI: 10.14309/ajg.0000000000000999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Li Y, Li Y, Wang D, Meng Q. Linc-POU3F3 is overexpressed in hepatocellular carcinoma and regulates cell proliferation, migration and invasion. Biomed Pharmacother 2018;105:683-9. [PMID: 29906746 DOI: 10.1016/j.biopha.2018.06.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
140 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
141 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
142 Li J, Zhang L, Sun Z, Ge Y, Xiao H, Xie Q, Hu S. Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: Initial experience and findings. J Contemp Brachytherapy 2020;12:233-40. [PMID: 32695194 DOI: 10.5114/jcb.2020.96863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Chen VL, Sharma P. Role of Biomarkers and Biopsy in Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:577-90. [DOI: 10.1016/j.cld.2020.07.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
144 Li Y, Chen J, Weng S, Yan C, Ye R, Zhu Y, Wen L, Cao D, Hong J. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 2021;9:55. [PMID: 33553348 DOI: 10.21037/atm.2020.02.38] [Reference Citation Analysis]
145 Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
146 Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A. Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study. J Gastroenterol 2021;56:181-90. [PMID: 33392749 DOI: 10.1007/s00535-020-01753-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
147 Rao C, Wang X, Li M, Zhou G, Gu H. Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2020;20:43. [PMID: 32345247 DOI: 10.1186/s12880-020-00433-y] [Reference Citation Analysis]
148 Shen Y, Wang H, Li W, Chen J. Prognostic significance of the CRP/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA.J Clin Lab Anal. 2019;33:e22999. [PMID: 31418936 DOI: 10.1002/jcla.22999] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
149 Yang Y, Zhou Y, Zhou C, Ma X. Deep learning radiomics based on contrast enhanced computed tomography predicts microvascular invasion and survival outcome in early stage hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00927-6. [PMID: 34862094 DOI: 10.1016/j.ejso.2021.11.120] [Reference Citation Analysis]
150 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Yao J, Hua X, Shi J, Hu X, Lui K, He K, Mai J, Lan T, Lu M. LncRNA THEMIS2-211, a tumor-originated circulating exosomal biomarker, promotes the growth and metastasis of hepatocellular carcinoma by functioning as a competing endogenous RNA. FASEB J 2022;36:e22238. [PMID: 35224785 DOI: 10.1096/fj.202101564R] [Reference Citation Analysis]
152 Shin SW, Cho SK, Hyun D, Park KB, Park HS, Do YS. Guidewire-catheter induced hydrodissection to assist radiofrequency ablation for subcapsular hepatocellular carcinoma with iodized oil retention in patients with failed artificial ascites due to perihepatic adhesion. Diagn Interv Radiol 2021;27:746-53. [PMID: 34792029 DOI: 10.5152/dir.2021.21056] [Reference Citation Analysis]
153 He L, Wang S, Ma X. The Influence of ICAM1 3'UTR Gene Polymorphism on the Occurrence and Metastasis of Primary Liver Cancer. Biomed Res Int 2021;2021:7377299. [PMID: 34869770 DOI: 10.1155/2021/7377299] [Reference Citation Analysis]
154 Jiang H, Song B, Qin Y, Chen J, Xiao D, Ha HI, Liu X, Oloruntoba-Sanders O, Erkanli A, Muir AJ, Bashir MR. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 2021;31:3638-48. [PMID: 33245494 DOI: 10.1007/s00330-020-07488-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
155 Caviglia GP, Ribaldone DG, Abate ML, Ciancio A, Pellicano R, Smedile A, Saracco GM. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis. Scandinavian Journal of Gastroenterology 2018;53:734-40. [DOI: 10.1080/00365521.2018.1459824] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
156 Czauderna C, Schmidtmann I, Koch S, Pilz L, Heinrich S, Otto G, Mittler J, Lang H, Kloeckner R, Düber C, Sprinzl MF, Worns MA, Galle PR, Marquardt JU, Weinmann A. High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J 2021. [PMID: 33709539 DOI: 10.1177/2050640620972611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 2021;31:4492-503. [PMID: 33409787 DOI: 10.1007/s00330-020-07468-3] [Reference Citation Analysis]
158 Tao Y, Li Y, Liu X, Deng Q, Yu Y, Yang Z. Nonsteroidal anti-inflammatory drugs, especially aspirin, are linked to lower risk and better survival of hepatocellular carcinoma: a meta-analysis. Cancer Manag Res 2018;10:2695-709. [PMID: 30147368 DOI: 10.2147/CMAR.S167560] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
159 Su TH, Peng CY, Chang SH, Tseng TC, Liu CJ, Chen CL, Liu CH, Yang HC, Chen PJ, Kao JH. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. J Formos Med Assoc 2021:S0929-6646(21)00361-2. [PMID: 34452785 DOI: 10.1016/j.jfma.2021.08.003] [Reference Citation Analysis]
160 Kang HJ, Lee JM, Yoon JH, Han JK. Role of Contrast-Enhanced Ultrasound as a Second-Line Diagnostic Modality in Noninvasive Diagnostic Algorithms for Hepatocellular Carcinoma. Korean J Radiol 2021;22:354-65. [PMID: 33236540 DOI: 10.3348/kjr.2020.0973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
161 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Reference Citation Analysis]
162 Yoon SM. External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. J Liver Cancer 2021;21:25-33. [DOI: 10.17998/jlc.21.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Li H, Sun J, Zhu H, Wu H, Zhang H, Gu Z, Luo K. Recent advances in development of dendritic polymer-based nanomedicines for cancer diagnosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2021;13:e1670. [PMID: 32949116 DOI: 10.1002/wnan.1670] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
164 Lin C. Does artificial ascites induce heat sink effect or electricity steal effect in the radiofrequency ablation of superficial liver tumor? Adv in Digestive Med 2019;6:141-3. [DOI: 10.1002/aid2.13167] [Reference Citation Analysis]
165 Jearth V, Patil PS, Mehta S, Sundaram S, Seth V, Goel M, Patkar S, Bal M, Rao V. Correlation of Clinicopathological Profile, Prognostic Factors, and Survival Outcomes with Baseline Alfa-Fetoprotein Levels in Patients With Hepatocellular Carcinoma: A Biomarker that is Bruised but Not Broken. Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.11.006] [Reference Citation Analysis]
166 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
167 Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125-137. [PMID: 30600478 DOI: 10.1007/s12072-018-9919-1] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 28.3] [Reference Citation Analysis]
168 Elpek GO. Orosomucoid in liver diseases. World J Gastroenterol 2021; 27(45): 7739-7747 [PMID: 34963738 DOI: 10.3748/wjg.v27.i45.7739] [Reference Citation Analysis]
169 Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. Sci Rep 2021;11:8184. [PMID: 33854160 DOI: 10.1038/s41598-021-87679-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
170 Luo J, Zhou K, Zhang B, Luo N, Bian J. Intravoxel Incoherent Motion Diffusion-Weighted Imaging for Evaluation of the Cell Density and Angiogenesis of Cirrhosis-Related Nodules in an Experimental Rat Model: Comparison and Correlation With Dynamic Contrast-Enhanced MRI. J Magn Reson Imaging 2020;51:812-23. [PMID: 31245888 DOI: 10.1002/jmri.26845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
171 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
172 Wu Z, Guo W, Chen S, Zhuang W. Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy. Invest New Drugs 2021;39:394-9. [PMID: 33006020 DOI: 10.1007/s10637-020-01009-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Chan KM, Wu TH, Cheng CH, Lee CF, Wu TJ, Chou HS, Lee WC. Implementation of sorafenib treatment for advanced hepatocellular carcinoma: an illustration of current practice in Taiwan. Cancer Manag Res 2019;11:1013-21. [PMID: 30774429 DOI: 10.2147/CMAR.S186678] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
174 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
175 Zhao T, Guo BJ, Xiao CL, Chen JJ, Lü C, Fang FF, Li B. Aerobic exercise suppresses hepatocellular carcinoma by downregulating dynamin-related protein 1 through PI3K/AKT pathway. J Integr Med 2021;19:418-27. [PMID: 34454893 DOI: 10.1016/j.joim.2021.08.003] [Reference Citation Analysis]
176 Imai K, Yamashita YI, Nakao Y, Matsumoto T, Kinoshita S, Yusa T, Kitano Y, Kaida T, Hayashi H, Baba H. Is Portal Vein Embolization Followed by Hepatectomy for Hepatocellular Carcinoma Justified in Patients with Impaired Liver Function? Ann Surg Oncol 2021;28:854-62. [PMID: 32740735 DOI: 10.1245/s10434-020-08960-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
177 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? World J Gastroenterol 2021; 27(33): 5536-5554 [PMID: 34588750 DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
178 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
179 Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis. Gastroenterology. 2018;155:1128-1139.e6. [PMID: 29981779 DOI: 10.1053/j.gastro.2018.06.079] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 12.5] [Reference Citation Analysis]
180 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
181 Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, Pryor DI. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol 2021;36:873-84. [PMID: 32632941 DOI: 10.1111/jgh.15175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
182 Lin M, Lu DS, Duan Y, Liao P, Sayre J, Xie X, Kuang M. Cirrhotic Nodule Transformation to Hepatocellular Carcinoma: Natural History and Predictive Biomarkers on Contrast-Enhanced Ultrasound. AJR Am J Roentgenol 2020;214:96-104. [PMID: 31642698 DOI: 10.2214/AJR.19.21739] [Reference Citation Analysis]
183 Wang Q, Zhang P, Li Z, Feng X, Lv C, Zhang H, Xiao H, Ding J, Chen X. Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models. Theranostics 2019;9:1426-52. [PMID: 30867842 DOI: 10.7150/thno.31683] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 11.7] [Reference Citation Analysis]
184 Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.Eur J Gastroenterol Hepatol. 2020;32:882-888. [PMID: 32395972 DOI: 10.1097/MEG.0000000000001685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
185 Chang SD, Cunha GM, Chernyak V. MR Imaging Contrast Agents: Role in Imaging of Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:329-45. [PMID: 34243921 DOI: 10.1016/j.mric.2021.05.014] [Reference Citation Analysis]
186 Zhong JH, Xing BC, Zhang WG, Chan AW, Chong CCN, Serenari M, Peng N, Huang T, Lu SD, Liang ZY, Huo RR, Wang YY, Cescon M, Liu TQ, Li L, Wu FX, Ma L, Ravaioli M, Neri J, Cucchetti A, Johnson PJ, Li LQ, Xiang BD. Repeat hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a retrospective multicentre study. Br J Surg 2021:znab340. [PMID: 34643677 DOI: 10.1093/bjs/znab340] [Reference Citation Analysis]
187 Jiang H, Yuan F, Zhao Z, Xue T, Ge N, Ren Z, Zhang L. Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma. Int J Gen Med 2021;14:9145-52. [PMID: 34880653 DOI: 10.2147/IJGM.S334378] [Reference Citation Analysis]
188 Chen Y, Xia Y, Tolat PP, Long L, Jiang Z, Huang Z, Tang Q. Comparison of Conventional Gadoxetate Disodium-Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion. AJR Am J Roentgenol 2021;216:1510-20. [PMID: 33826360 DOI: 10.2214/AJR.20.23255] [Reference Citation Analysis]
189 Zhang W, Liu Z, Chen J, Dong S, Cen B, Zheng S, Xu X. A preoperative model for predicting microvascular invasion and assisting in prognostic stratification in liver transplantation for HCC regarding empirical criteria. Transl Oncol 2021;14:101200. [PMID: 34399173 DOI: 10.1016/j.tranon.2021.101200] [Reference Citation Analysis]
190 Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol 2019;42:1563-70. [PMID: 31455987 DOI: 10.1007/s00270-019-02317-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
191 Kim DH, Kim B, Youn SY, Kim H, Choi JI. Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1763. [PMID: 34679461 DOI: 10.3390/diagnostics11101763] [Reference Citation Analysis]
192 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
193 Jeon SK, Joo I, Bae JS, Park SJ, Lee JM. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Eur Radiol 2021. [PMID: 34132875 DOI: 10.1007/s00330-021-08116-0] [Reference Citation Analysis]
194 Park S, Rim CH, Jung YK, Yoon WS. Therapeutic Decision Making in Hepatocellular Carcinoma According to Age and Child-Pugh Class: A Nationwide Cohort Analysis in South Korea. Can J Gastroenterol Hepatol 2021;2021:6640121. [PMID: 33505941 DOI: 10.1155/2021/6640121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Shiha G, Soliman R, Mikhail N, Hassan A, Eslam M. Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk-based surveillance using pre- and post-treatment general evaluation score. Liver Int 2021. [PMID: 34174150 DOI: 10.1111/liv.14995] [Reference Citation Analysis]
196 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
197 Hanouneh IA, Alkhouri N, Singal AG. Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm? Clin Mol Hepatol. 2019;25:264-269. [PMID: 30827081 DOI: 10.3350/cmh.2019.1001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
198 Kanwal F, Singal AG. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction. Gastroenterology 2019;157:54-64. [PMID: 30986389 DOI: 10.1053/j.gastro.2019.02.049] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 31.3] [Reference Citation Analysis]
199 Cheung TT. Laparoscopic liver resection in patients with liver cirrhosis-the path towards standard of care. Hepatobiliary Surg Nutr 2018;7:68-9. [PMID: 29531952 DOI: 10.21037/hbsn.2017.09.02] [Reference Citation Analysis]
200 Peng J, Kang S, Ning Z, Deng H, Shen J, Xu Y, Zhang J, Zhao W, Li X, Gong W, Huang J, Liu L. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging. Eur Radiol. 2020;30:413-424. [PMID: 31332558 DOI: 10.1007/s00330-019-06318-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
201 Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, Chang ML, Lin CL, Yeh CT. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int 2022. [PMID: 34982369 DOI: 10.1007/s12072-021-10283-7] [Reference Citation Analysis]
202 Inchingolo R, Faletti R, Grazioli L, Tricarico E, Gatti M, Pecorelli A, Ippolito D. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients. World J Hepatol 2018;10:462-73. [PMID: 30079132 DOI: 10.4254/wjh.v10.i7.462] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
203 Li Y, Xu Z, An C, Chen H, Li X. Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization. JPM 2022;12:248. [DOI: 10.3390/jpm12020248] [Reference Citation Analysis]
204 Spreafico C, Sposito C, Vaiani M, Cascella T, Bhoori S, Morosi C, Lanocita R, Romito R, Chiesa C, Maccauro M, Marchianò A, Mazzaferro V. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol 2018;68:724-32. [PMID: 29331342 DOI: 10.1016/j.jhep.2017.12.026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 13.3] [Reference Citation Analysis]
205 Kuo SC, Lin CN, Lin YJ, Chen WY, Hwang JS, Wang JD. Optimal Intervals of Ultrasonography Screening for Early Diagnosis of Hepatocellular Carcinoma in Taiwan. JAMA Netw Open 2021;4:e2114680. [PMID: 34165580 DOI: 10.1001/jamanetworkopen.2021.14680] [Reference Citation Analysis]
206 Yamashita YI, Hayashi H, Imai K, Okabe H, Nakagawa S, Kitamura F, Uemura N, Nakao Y, Yusa T, Itoyama R, Yamao T, Umesaki N, Miyata T, Chikamoto A, Shimokawa M, Baba H. Perioperative Allogeneic Blood Transfusion Does not Influence Patient Survival After Hepatectomy for Hepatocellular Carcinoma: A Propensity Score Matching Analysis. World J Surg 2019;43:2894-901. [PMID: 31312946 DOI: 10.1007/s00268-019-05085-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
207 Sun SW, Liu QP, Xu X, Zhu FP, Zhang YD, Liu XS. Direct Comparison of Four Presurgical Stratifying Schemes for Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced MRI. J Magn Reson Imaging 2020;52:433-47. [PMID: 31943465 DOI: 10.1002/jmri.27043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
208 Kim NJ, Jacob DA, Ioannou GN, John BV, Rogal S, Rozenberg-Ben-Dror K. Rates and Predictors of Undergoing Different Hepatocellular Carcinoma Screening Tests in Patients With Cirrhosis. Am J Gastroenterol 2021;116:411-5. [PMID: 33252455 DOI: 10.14309/ajg.0000000000001000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
209 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
210 Jiang H, Liu X, Chen J, Wei Y, Lee JM, Cao L, Wu Y, Duan T, Li X, Ma L, Song B. Man or machine?Cancer Imaging. 2019;19:84. [PMID: 31806050 DOI: 10.1186/s40644-019-0266-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
211 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Choi JI. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. Cancers (Basel) 2021;13:2975. [PMID: 34198589 DOI: 10.3390/cancers13122975] [Reference Citation Analysis]
212 Kim AK, Hamilton JP, Lin SY, Chang T, Hann H, Hu C, Lou Y, Lin Y, Gade TP, Park G, Luu H, Lee T, Wang J, Chen D, Goggins MG, Jain S, Song W, Su Y. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. [DOI: 10.1038/s41416-022-01706-9] [Reference Citation Analysis]
213 Ren S, Qi Q, Liu S, Duan S, Mao B, Chang Z, Zhang Y, Wang S, Zhang L. Preoperative prediction of pathological grading of hepatocellular carcinoma using machine learning-based ultrasomics: A multicenter study. Eur J Radiol 2021;143:109891. [PMID: 34481117 DOI: 10.1016/j.ejrad.2021.109891] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Yu C, Song C, Lv J, Zhu M, Yu C, Guo Y, Yang L, Chen Y, Chen Z, Jiang T, Ma H, Jin G, Shen H, Hu Z, Li L; China Kadoorie Biobank Collaborative Group. Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people. Int J Cancer 2021;148:2924-34. [PMID: 33521941 DOI: 10.1002/ijc.33487] [Reference Citation Analysis]
215 Kuroda H, Nagasawa T, Fujiwara Y, Sato H, Abe T, Kooka Y, Endo K, Oikawa T, Sawara K, Takikawa Y. Comparing the Safety and Efficacy of Microwave Ablation Using ThermosphereTM Technology versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers (Basel) 2021;13:1295. [PMID: 33803926 DOI: 10.3390/cancers13061295] [Reference Citation Analysis]
216 Decraecker M, Toulouse C, Blanc JF. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers (Basel) 2021;13:6310. [PMID: 34944930 DOI: 10.3390/cancers13246310] [Reference Citation Analysis]
217 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
218 Ueno Y. New treatment-induced adverse effects we need to learn as modern hepatologists. Hepatol Int 2019;13:391-4. [PMID: 31016539 DOI: 10.1007/s12072-019-09947-2] [Reference Citation Analysis]
219 Mai RY, Wang YY, Bai T, Chen J, Xiang BD, Wu GB, Wu FX, Li LQ, Ye JZ. Combination Of ALBI And APRI To Predict Post-Hepatectomy Liver Failure After Liver Resection For HBV-Related HCC Patients. Cancer Manag Res. 2019;11:8799-8806. [PMID: 31632139 DOI: 10.2147/cmar.s213432] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
220 Mishima K, Itano O, Matsuda S, Suzuki S, Onishi A, Tamura M, Inoue M, Abe Y, Yagi H, Hibi T, Kitago M, Shinoda M, Kitagawa Y. Development of human hepatocellular carcinoma in X-linked severe combined immunodeficient pigs: An orthotopic xenograft model. PLoS One 2021;16:e0248352. [PMID: 33750947 DOI: 10.1371/journal.pone.0248352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Nakano C, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis. Nutrients 2018;10:E1072. [PMID: 30103528 DOI: 10.3390/nu10081072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
222 Ogasawara S, Choo SP, Li JT, Yoo C, Wang B, Lee D, Chow PKH. Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion. Cancers (Basel) 2021;13:2626. [PMID: 34071818 DOI: 10.3390/cancers13112626] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Liu YE, Zong J, Chen XJ, Zhang R, Ren XC, Guo ZJ, Liu CX, Lin Q. Cryoablation combined with radiotherapy for hepatic malignancy: Five case reports. World J Gastrointest Oncol 2020; 12(2): 237-247 [PMID: 32104554 DOI: 10.4251/wjgo.v12.i2.237] [Reference Citation Analysis]
224 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
225 Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, Torimura T. High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma. Hepatol Res 2019;49:1046-53. [PMID: 30993774 DOI: 10.1111/hepr.13350] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
226 Dong Y, Zuo D, Qiu YJ, Cao JY, Wang HZ, Yu LY, Wang WP. Preoperative prediction of microvascular invasion (MVI) in hepatocellular carcinoma based on kupffer phase radiomic features of sonazoid contrast-enhanced ultrasound (SCEUS): A prospective study. Clin Hemorheol Microcirc 2022. [PMID: 35001883 DOI: 10.3233/CH-211363] [Reference Citation Analysis]
227 Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
228 Campani C, Bensi C, Milani S, Galli A, Tarocchi M. Resection of NAFLD-Associated HCC: Patient Selection and Reported Outcomes. J Hepatocell Carcinoma 2020;7:107-16. [PMID: 32802809 DOI: 10.2147/JHC.S252506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
229 Low HM, Choi JY, Tan CH. Pathological variants of hepatocellular carcinoma on MRI: emphasis on histopathologic correlation. Abdom Radiol (NY) 2019;44:493-508. [PMID: 30145629 DOI: 10.1007/s00261-018-1749-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
230 Zhuang L, Yang Z, Meng Z. Upregulation of BUB1B, CCNB1, CDC7, CDC20, and MCM3 in Tumor Tissues Predicted Worse Overall Survival and Disease-Free Survival in Hepatocellular Carcinoma Patients. Biomed Res Int 2018;2018:7897346. [PMID: 30363964 DOI: 10.1155/2018/7897346] [Cited by in Crossref: 50] [Cited by in F6Publishing: 59] [Article Influence: 12.5] [Reference Citation Analysis]
231 Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 2021;51:880-9. [PMID: 33837620 DOI: 10.1111/hepr.13644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
232 Wang Z, Yu XL, Zhang J, Cheng ZG, Han ZY, Liu FY, Dou JP, Kong Y, Dong XJ, Zhao QX, Yu J, Liang P, Tang WZ. Huaier granule prevents the recurrence of early-stage hepatocellular carcinoma after thermal ablation: A cohort study. J Ethnopharmacol 2021;281:114539. [PMID: 34428522 DOI: 10.1016/j.jep.2021.114539] [Reference Citation Analysis]
233 Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng J, Feletto E, Canfell K, Qu C, Chen W. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer 2021;148:1051-65. [PMID: 32997794 DOI: 10.1002/ijc.33313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
234 Feldman AM, Modh A, Glide-Hurst C, Chetty IJ, Movsas B. Real-time Magnetic Resonance-guided Liver Stereotactic Body Radiation Therapy: An Institutional Report Using a Magnetic Resonance-Linac System. Cureus 2019;11:e5774. [PMID: 31723533 DOI: 10.7759/cureus.5774] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
235 Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF, Yu ML. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Med 2021. [PMID: 34786871 DOI: 10.1002/cam4.4430] [Reference Citation Analysis]
236 Shen S, Luo X, Gao K, Sun Y, Yao D, Zhu L. Identification and integrative analysis of microRNAs and mRNAs involved in proliferation and invasion of pressure‑treated human liver cancer cell lines. Mol Med Rep 2019;20:375-87. [PMID: 31115518 DOI: 10.3892/mmr.2019.10223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
237 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
238 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
239 Jogi S, Varanai R, Bantu SS, Manne A. Selecting the first line treatment in non-metastatic hepatocellular carcinoma - comparing clinical practice guidelines. Oncol Rev 2020;14:515. [PMID: 33425223 DOI: 10.4081/oncol.2020.515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Tachi K, Agyei-Nkansah A, Archampong T. Hepatocellular carcinoma in Ghana: a retrospective analysis of a tertiary hospital data. Pan Afr Med J 2020;36:43. [PMID: 32774619 DOI: 10.11604/pamj.2020.36.43.21085] [Reference Citation Analysis]
241 Geyer T, Rübenthaler J, Marschner C, von Hake M, Fabritius MP, Froelich MF, Huber T, Nörenberg D, Rückel J, Weniger M, Martens C, Sabel L, Clevert DA, Schwarze V. Structured Reporting Using CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma (HCC)-Impact and Advantages on Report Integrity, Quality and Interdisciplinary Communication. Cancers (Basel) 2021;13:534. [PMID: 33572502 DOI: 10.3390/cancers13030534] [Reference Citation Analysis]
242 Zhang R, Xu L, Wen X, Zhang J, Yang P, Zhang L, Xue X, Wang X, Huang Q, Guo C, Shi Y, Niu T, Chen F. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.Quant Imaging Med Surg. 2019;9:1503-1515. [PMID: 31667137 DOI: 10.21037/qims.2019.09.07] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
243 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
244 Takaoka M. Commentary on: "Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - a retrospective cohort study". Int J Surg 2019;71:168. [PMID: 31574304 DOI: 10.1016/j.ijsu.2019.09.027] [Reference Citation Analysis]
245 Costentin CE, Nahon P. HCC risk prediction using biomarkers in non-cirrhotic patients following HCV eradication: Reassuring the patient or the doctor? JHEP Rep 2021;3:100320. [PMID: 34308325 DOI: 10.1016/j.jhepr.2021.100320] [Reference Citation Analysis]
246 Jin YJ, Aycheh HM, Han S, Chamberlin J, Shin J, Byun S, Lee Y. Differential alternative splicing between hepatocellular carcinoma with normal and elevated serum alpha-fetoprotein. BMC Med Genomics 2020;13:194. [PMID: 33371894 DOI: 10.1186/s12920-020-00836-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Reference Citation Analysis]
248 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
249 Hu C, Song Y, Zhang J, Dai L, Tang C, Li M, Liao W, Zhou Y, Xu Y, Zhang YY, Zhou Y. Preoperative Gadoxetic Acid-Enhanced MRI Based Nomogram Improves Prediction of Early HCC Recurrence After Ablation Therapy. Front Oncol 2021;11:649682. [PMID: 34094938 DOI: 10.3389/fonc.2021.649682] [Reference Citation Analysis]
250 Balaceanu LA. Biomarkers vs imaging in the early detection of hepatocellular carcinoma and prognosis. World J Clin Cases 2019; 7(12): 1367-1382 [PMID: 31363465 DOI: 10.12998/wjcc.v7.i12.1367] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
251 Burciu C, Șirli R, Bende F, Fofiu R, Popescu A, Sporea I, Ghiuchici A, Miuțescu B, Dănilă M. Usefulness of Imaging and Biological Tools for the Characterization of Portal Vein Thrombosis in Hepatocellular Carcinoma. Diagnostics 2022;12:1145. [DOI: 10.3390/diagnostics12051145] [Reference Citation Analysis]
252 Schauer C, van Rijnsoever M, Gane E. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand. J Viral Hepat 2019;26:1372-6. [PMID: 31323163 DOI: 10.1111/jvh.13179] [Reference Citation Analysis]
253 Novick D, Rajan N, Wei A, Cheng R, Szende A, Baik R, Colman S. Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan. Value Health Reg Issues 2022;30:76-82. [PMID: 35278836 DOI: 10.1016/j.vhri.2022.01.001] [Reference Citation Analysis]
254 Zhang Y, Wang C, Xu H, Xiao P, Gao Y. Hepatocellular carcinoma in the noncirrhotic liver: a literature review. Eur J Gastroenterol Hepatol 2019;31:743-8. [PMID: 31008808 DOI: 10.1097/MEG.0000000000001419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
255 Kanogawa N, Ogasawara S, Ooka Y, Inoue M, Wakamatsu T, Yokoyama M, Maruta S, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Koroki K, Kanzaki H, Maeda T, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Saito T, Motoyama T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Takemura R, Nozaki-Taguchi N, Shiroh I, Yokosuka O, Kato N. Propofol versus midazolam for sedation during radiofrequency ablation in patients with hepatocellular carcinoma. JGH Open 2021;5:273-9. [PMID: 33553667 DOI: 10.1002/jgh3.12483] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Foerster F, Galle PR. Hepatocellular carcinoma: one world, one cancer-different guidelines? Hepatobiliary Surg Nutr 2018;7:41-3. [PMID: 29532810 DOI: 10.21037/hbsn.2018.01.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
257 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Karp SJ, Moriyama M, Kogure H. Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. Cancers 2022;14:2549. [DOI: 10.3390/cancers14102549] [Reference Citation Analysis]
258 Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma 2021;8:1565-77. [PMID: 34909425 DOI: 10.2147/JHC.S335879] [Reference Citation Analysis]
259 Cai M, Li B, Lin L, Huang J, An Y, Huang W, Zhou Z, Wang Y, Shuai X, Zhu K. A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomater Sci 2020;8:3485-99. [PMID: 32432234 DOI: 10.1039/d0bm00295j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
260 Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H, Huang Y, Tai C, Peng C, Bair M, Chen C, Yeh M, Lin C, Lin C, Lee P, Chong L, Hung C, Chang TS, Huang J, Yang C, Hu J, Lin C, Chen C, Wang C, Su W, Hsieh T, Lin C, Tsai W, Lee T, Chen G, Wang S, Chang C, Mo L, Yang S, Wu W, Huang C, Hsiung C, Kao C, Tsai P, Liu C, Lee M, Liu C, Dai C, Chuang W, Lin H, Kao J, Yu M. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.01.012] [Reference Citation Analysis]
261 Jensen C, Holm Nielsen S, Eslam M, Genovese F, Nielsen MJ, Vongsuvanh R, Uchila R, van der Poorten D, George J, Karsdal MA, Leeming DJ, Willumsen N. Cross-Linked Multimeric Pro-Peptides of Type III Collagen (PC3X) in Hepatocellular Carcinoma - A Biomarker That Provides Additional Prognostic Value in AFP Positive Patients. J Hepatocell Carcinoma 2020;7:301-13. [PMID: 33204663 DOI: 10.2147/JHC.S275008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
262 Zhao C, Dai H, Shao J, He Q, Su W, Wang P, Tang Q, Zeng J, Xu S, Zhao J, Xiang S. Accuracy of Various Forms of Contrast-Enhanced MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:680691. [PMID: 34950573 DOI: 10.3389/fonc.2021.680691] [Reference Citation Analysis]
263 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Ding R, Chen T, Zhang Y, Chen X, Zhuang L, Yang Z. HMGCS2 in metabolic pathways was associated with overall survival in hepatocellular carcinoma: A LASSO-derived study. Sci Prog 2021;104:368504211031749. [PMID: 34260294 DOI: 10.1177/00368504211031749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Fang Y, Yuan XD, Liu HH, Xiang L, Chen LM, Fan YC, Gao S, Wang K. 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection. Expert Rev Clin Immunol 2021;17:177-85. [PMID: 33353450 DOI: 10.1080/1744666X.2020.1866987] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Lao XM. Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization. Cancer Med 2019;8:5097-107. [PMID: 31313476 DOI: 10.1002/cam4.2380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
267 Hao W, Binbin J, Wei Y, Kun Y. Can Radiofrequency Ablation Replace Liver Resection for Solitary Colorectal Liver Metastasis? A Systemic Review and Meta-Analysis. Front Oncol 2020;10:561669. [PMID: 33312946 DOI: 10.3389/fonc.2020.561669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Liu M, Wu R, Liu X, Xu H, Chi X, Wang X, Zhan M, Wang B, Peng F, Gao X, Shi Y, Wen X, Ji Y, Jin Q, Niu J. Validation of the GALAD Model and Establishment of GAAP Model for Diagnosis of Hepatocellular Carcinoma in Chinese Patients. J Hepatocell Carcinoma 2020;7:219-32. [PMID: 33123501 DOI: 10.2147/JHC.S271790] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
269 Zhong BY, Yan ZP, Sun JH, Zhang L, Hou ZH, Yang MJ, Zhou GH, Wang WS, Li Z, Huang P, Zhang S, Zhu XL, Ni CF. Prognostic Performance of Albumin-Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib. Front Oncol 2020;10:525461. [PMID: 33392064 DOI: 10.3389/fonc.2020.525461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
270 Masuzaki R, Kanda T, Sasaki R, Matsumoto N, Nirei K, Ogawa M, Moriyama M. Application of artificial intelligence in hepatology: Minireview. Artif Intell Gastroenterol 2020; 1(1): 5-11 [DOI: 10.35712/aig.v1.i1.5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
271 Rimola J, Forner A. Hepatobiliary contrast agents in MR: Where we stand and future perspectives. Liver Int 2021;41:888-90. [PMID: 33861894 DOI: 10.1111/liv.14883] [Reference Citation Analysis]
272 He Y, Hu B, Zhu C, Xu W, Ge Y, Hao X, Dong B, Chen X, Dong Q, Zhou X. A Novel Multimodal Radiomics Model for Predicting Prognosis of Resected Hepatocellular Carcinoma. Front Oncol 2022;12:745258. [DOI: 10.3389/fonc.2022.745258] [Reference Citation Analysis]
273 Carr BI, Akkiz H, Üsküdar O, Yalçın K, Guerra V, Kuran S, Karaoğullarından Ü, Altıntaş E, Özakyol A, Tokmak S, Ballı T, Yücesoy M, Bahçeci Hİ, Ülkü A, Akçam T, Polat KY, Ekinci N, Şimşek H, Örmeci N, Sonsuz A, Demir M, Kılıç M, Uygun A, Demir A, Delik A, Arslan B, Doran F, Yilmaz S, Tokat Y. HCC with low- and normal-serum alpha-fetoprotein levels. Clin Pract (Lond). 2018;15:453-464. [PMID: 29576865 DOI: 10.4172/clinical-practice.1000393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
274 Wu JY, Yin ZY, Bai YN, Chen YF, Zhou SQ, Wang SJ, Zhou JY, Li YN, Qiu FN, Li B, Yan ML. Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Hepatocell Carcinoma 2021;8:1233-40. [PMID: 34676181 DOI: 10.2147/JHC.S332420] [Reference Citation Analysis]
275 Gong XQ, Tao YY, Wu YK, Liu N, Yu X, Wang R, Zheng J, Liu N, Huang XH, Li JD, Yang G, Wei XQ, Yang L, Zhang XM. Progress of MRI Radiomics in Hepatocellular Carcinoma. Front Oncol 2021;11:698373. [PMID: 34616673 DOI: 10.3389/fonc.2021.698373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
276 Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
277 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Chon HY, Seo YS, Lee JI, Kim BS, Jang BK, Kim SG, Suk KT, Kim IH, Lee JW, Chon YE, Kim MY, Jeong SW, Lee HA, Yim SY, Um SH, Lee HW, Lee KS, Song JE, Lee CH, Chung WJ, Hwang JS, Yoo JJ, Kim YS, Kim DJ, Lee CH, Yu JH, Ha YJ, Kim MN, Lee JH, Hwang SG, Kang SH, Baik SK, Jang JY, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU; Korean Transient Elastography Study Group. Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2021;33:885-93. [PMID: 32541238 DOI: 10.1097/MEG.0000000000001794] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
279 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
280 Chai Y, Li K, Zhang C, Chen S, Ma K. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer 2019;19:497. [PMID: 31133001 DOI: 10.1186/s12885-019-5707-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
281 Buranupakorn T, Thangsuk P, Patumanond J, Phinyo P. Emulation of a Target Trial to Evaluate the Causal Effect of Palliative Care Consultation on the Survival Time of Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:992. [PMID: 33673534 DOI: 10.3390/cancers13050992] [Reference Citation Analysis]
282 Lin N, Lin Y, Xu J, Liu D, Li D, Meng H, Gallant MA, Kubota N, Roy D, Li JS, Gorospe EC, Sherman M, Gish RG, Abou-Alfa GK, Nguyen MH, Taggart DJ, Van Etten RA, Hoshida Y, Li W. A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinoma. Hepatol Commun 2022. [PMID: 35244350 DOI: 10.1002/hep4.1918] [Reference Citation Analysis]
283 Nishikawa H, Shiraki M, Hiramatsu A, Hara N, Moriya K, Hino K, Koike K. Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. Hepatol Res 2021;51:957-67. [PMID: 34057800 DOI: 10.1111/hepr.13679] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
284 Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Switching to systemic therapy after locoregional treatment failure: Definition and best timing. Clin Mol Hepatol. 2020;26:155-162. [PMID: 31937081 DOI: 10.3350/cmh.2019.0021n] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
285 D'Ambrosio R, Aghemo A, Rumi MG, Degasperi E, Sangiovanni A, Maggioni M, Fraquelli M, Perbellini R, Rosenberg W, Bedossa P, Colombo M, Lampertico P. Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression. Liver Int. 2018;38:1459-1467. [PMID: 29377616 DOI: 10.1111/liv.13707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
286 Chen J, Ding Y, Huang F, Lan R, Wang Z, Huang W, Chen R, Wu B, Fu L, Yang Y, Liu J, Hong J, Zhang W, Zhang L. Irradiated whole-cell vaccine suppresses hepatocellular carcinoma growth in mice via Th9 cells. Oncol Lett 2021;21:409. [PMID: 33841570 DOI: 10.3892/ol.2021.12670] [Reference Citation Analysis]
287 Su TH, Wu CH, Kao JH. Artificial intelligence in precision medicine in hepatology. J Gastroenterol Hepatol 2021;36:569-80. [PMID: 33709606 DOI: 10.1111/jgh.15415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
288 Zhou G, Zeng Y, Luo Y, Guo S, Bao L, Zhang Q. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma. Eur J Surg Oncol 2021:S0748-7983(21)00579-5. [PMID: 34175168 DOI: 10.1016/j.ejso.2021.06.015] [Reference Citation Analysis]
289 Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, Ito T, Tanaka T, Miyake N, Zou B, Wong C, Toyoda H, Esquivel CO, Bonham CA, Nguyen MH, Huang DQ. Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun 2022. [PMID: 35234371 DOI: 10.1002/hep4.1923] [Reference Citation Analysis]
290 Xing H, Qiu H, Ding X, Han J, Li Z, Wu H, Yan C, Li H, Han R, Zhang H, Li C, Wang M, Wu M, Shen F, Zheng Y, Yang T. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma. Biomark Med 2019;13:545-55. [PMID: 31140827 DOI: 10.2217/bmm-2018-0414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
291 Syed YY. Ramucirumab: A Review in Hepatocellular Carcinoma. Drugs 2020;80:315-22. [DOI: 10.1007/s40265-020-01263-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
292 Zheng Y, Xu M, Zeng D, Tong H, Shi Y, Feng Y, Zhang X. In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma. Diagn Pathol 2022;17:11. [PMID: 35034659 DOI: 10.1186/s13000-022-01194-8] [Reference Citation Analysis]
293 Son J, Hwang SH, Park S, Han K, Chung YE, Choi J, Kim M, Park M. Imaging Features of Hepatocellular Carcinoma: Quantitative and Qualitative Comparison Between MRI-Enhanced With Gd-EOB-DTPA and Gd-DTPA. Investigative Radiology 2019;54:494-9. [DOI: 10.1097/rli.0000000000000562] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
294 Liu T, Shao Y, Lu L, Shen Y, Hsu C, Lin Z, Hsu C, Cheng A. Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2019;13:615-21. [DOI: 10.1080/17474124.2019.1621165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
295 Yang JD. Detect or not to detect very early stage hepatocellular carcinoma? The western perspective. Clin Mol Hepatol 2019;25:335-43. [PMID: 30924328 DOI: 10.3350/cmh.2019.0010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
296 Chen D, Yan Y, Wang X, Li S, Liu Y, Yu D, He Y, Deng R, Liu Y, Xu M, Luo J, Gao H, Wang S. Chronic alcohol exposure promotes HCC stemness and metastasis through β-catenin/miR-22-3p/TET2 axis. Aging (Albany NY) 2021;13:14433-55. [PMID: 34019487 DOI: 10.18632/aging.203059] [Reference Citation Analysis]
297 Li B, Zhao Y, Cai W, Ming A, Li H. Validation and update of a multivariable prediction model for the identification and management of patients at risk for hepatocellular carcinoma. Clin Proteomics 2021;18:21. [PMID: 34412596 DOI: 10.1186/s12014-021-09326-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
298 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
299 Wu C, Luo Y, Chen Y, Qu H, Zheng L, Yao J. Development of a prognostic gene signature for hepatocellular carcinoma. Cancer Treat Res Commun 2022;31:100511. [PMID: 35030478 DOI: 10.1016/j.ctarc.2022.100511] [Reference Citation Analysis]
300 Jiang Z, Zhang Y, Liu X, Liang J, Qiu G, Zhu X, Chen J, Li L. Identification of a Functional ceRNA Network to Explore Potential Biomarkers for Hepatocellular Carcinoma. Onco Targets Ther 2020;13:12341-55. [PMID: 33293827 DOI: 10.2147/OTT.S278912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Yu JH, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR, An HY, Lee JW. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol. 2019;31:865-872. [PMID: 30694912 DOI: 10.1097/meg.0000000000001357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
302 Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules 2020;10:E1673. [PMID: 33333800 DOI: 10.3390/biom10121673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
303 Lu SD, Li L, Liang XM, Chen W, Chen FL, Fan LL, Ahir BK, Zhang WG, Zhong JH. Updates and advancements in the management of hepatocellular carcinoma patients after hepatectomy. Expert Rev Gastroenterol Hepatol 2019;13:1077-88. [PMID: 31648568 DOI: 10.1080/17474124.2019.1684898] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Chen Y, Qin X, Long L, Zhang L, Huang Z, Jiang Z, Li C. Diagnostic Value of Gd‐EOB‐DTPA‐Enhanced MRI for the Expression of Ki67 and Microvascular Density in Hepatocellular Carcinoma. J Magn Reson Imaging 2020;51:1755-63. [DOI: 10.1002/jmri.26974] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
305 Shen T, Lu Y, Zhang Q. High Squalene Epoxidase in Tumors Predicts Worse Survival in Patients With Hepatocellular Carcinoma: Integrated Bioinformatic Analysis on NAFLD and HCC. Cancer Control 2020;27:1073274820914663. [PMID: 32216563 DOI: 10.1177/1073274820914663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
306 Bartolotta TV, Terranova MC, Gagliardo C, Taibbi A. CEUS LI-RADS: a pictorial review. Insights Imaging. 2020;11:9. [PMID: 32020352 DOI: 10.1186/s13244-019-0819-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
307 Zou ZM, Chang DH, Liu H, Xiao YD. Current updates in machine learning in the prediction of therapeutic outcome of hepatocellular carcinoma: what should we know? Insights Imaging 2021;12:31. [PMID: 33675433 DOI: 10.1186/s13244-021-00977-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
308 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases 2018; 6(6): 110-120 [PMID: 29988930 DOI: 10.12998/wjcc.v6.i6.110] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
309 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
310 Osho A, Rich NE, Singal AG. Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. Hepatoma Res 2020;6:55. [PMID: 32944652 DOI: 10.20517/2394-5079.2020.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Zhang Z, Chen P, Xie H, Cao P. Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta-analysis. Cancer Med 2020;9:1349-64. [PMID: 31876977 DOI: 10.1002/cam4.2799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
312 Shi K, Liu Y, Wang X, Li Y, Zhang Q, Hu Y, Ran C, Huang Y, Hou J, Wang X. Adjuvant Fuzheng Huayu Capsule Reduces the Incidence of Hepatocellular Carcinoma in Patients with Hepatitis B-Caused Cirrhosis. Evid Based Complement Alternat Med 2020;2020:8826091. [PMID: 33178324 DOI: 10.1155/2020/8826091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
313 Rutledge B, Jan J, Benjaram S, Sahni N, Naylor P, Philip P, Ehrinpreis M, Mutchnick M. Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center. J Gastrointest Cancer 2020;51:972-9. [PMID: 31792736 DOI: 10.1007/s12029-019-00342-6] [Reference Citation Analysis]
314 Geist BK, Xing H, Wang J, Shi X, Zhao H, Hacker M, Sang X, Huo L, Li X. A methodological investigation of healthy tissue, hepatocellular carcinoma, and other lesions with dynamic 68Ga-FAPI-04 PET/CT imaging. EJNMMI Phys 2021;8:8. [PMID: 33483880 DOI: 10.1186/s40658-021-00353-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Wang Z, Peng Y, Hu J, Wang X, Sun H, Sun J, Shi Y, Xiao Y, Ding Z, Yang X, Tang M, Tang Z, Wang J, Lau WY, Fan J, Zhou J. Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma: A Single Center Study of 45 Patients. Ann Surg. 2018;. [PMID: 29995681 DOI: 10.1097/sla.0000000000002942] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
316 Mezale D, Strumfa I, Vanags A, Kalva A, Balodis D, Strumfs B, Fridrihsone I, Abolins A, Gardovskis J. Diagnostic Algorithm of Hepatocellular Carcinoma: Classics and Innovations in Radiology and Pathology. In: Teodor Streba C, Constantin Vere C, Rogoveanu I, editors. Hepatocellular Carcinoma - Advances in Diagnosis and Treatment. IntechOpen; 2018. [DOI: 10.5772/intechopen.76136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
317 Chaikajornwat J, Tanasoontrarat W, Phathong C, Pinjaroen N, Chaiteerakij R. Clinical outcome of Yttrium-90 selective internal radiation therapy (Y-90 SIRT) in unresectable hepatocellular carcinoma: Experience from a tertiary care center. Liver Research 2021. [DOI: 10.1016/j.livres.2021.07.001] [Reference Citation Analysis]
318 Yu CL, Weng MS, Chen WC, Chien KT, Chi CW, Chung CH, Huang CW, Wang PC, Chen CC, Tsai AC, Liu SC, Wang SW. Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-κB-Dependent Pathway. Int J Mol Sci 2021;22:2930. [PMID: 33805784 DOI: 10.3390/ijms22062930] [Reference Citation Analysis]
319 Manzini G, Hines IN, Henne-Bruns D, Kremer M. Resection or radiofrequency ablation for hepatocellular carcinoma? Assessment of validity of current studies, meta-analyses and their influence on guidelines. HPB (Oxford) 2020;22:1206-15. [PMID: 31959487 DOI: 10.1016/j.hpb.2019.12.009] [Reference Citation Analysis]
320 Ni Q, Chen Z, Zheng Q, Xie D, Li JJ, Cheng S, Ma X. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Cancer Sci 2020;111:1500-13. [PMID: 31997489 DOI: 10.1111/cas.14331] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
321 Müller M, Bird TG, Nault JC. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. J Hepatol 2020;72:990-1002. [PMID: 32044402 DOI: 10.1016/j.jhep.2020.01.019] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
322 Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, Yu ML. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. PLoS One 2018;13:e0202650. [PMID: 30180193 DOI: 10.1371/journal.pone.0202650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
323 Delvecchio A, Inchingolo R, Laforgia R, Ratti F, Gelli M, Anelli MF, Laurent A, Vitali G, Magistri P, Assirati G, Felli E, Wakabayashi T, Pessaux P, Piardi T, di Benedetto F, de'Angelis N, Briceño J, Rampoldi A, Adam R, Cherqui D, Aldrighetti LA, Memeo R. Liver resection vs radiofrequency ablation in single hepatocellular carcinoma of posterosuperior segments in elderly patients. World J Gastrointest Surg 2021;13:1696-707. [PMID: 35070074 DOI: 10.4240/wjgs.v13.i12.1696] [Reference Citation Analysis]
324 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
325 Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol 2021. [PMID: 34396706 DOI: 10.1111/1754-9485.13309] [Reference Citation Analysis]
326 Nadarevic T, Colli A, Giljaca V, Fraquelli M, Casazza G, Manzotti C, Štimac D, Miletic D. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2022;5:CD014798. [PMID: 35521901 DOI: 10.1002/14651858.CD014798.pub2] [Reference Citation Analysis]
327 Li AA, Kim D, Kim W, Dibba P, Wong K, Cholankeril G, Jacobson IM, Younossi ZM, Ahmed A. Disparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016. J Viral Hepat 2018;25:1608-16. [PMID: 30112849 DOI: 10.1111/jvh.12981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
328 Chen ZX, Jian ZW, Wu XW, Wang JC, Peng JY, Huang CY, Lao XM. Impact of overweightness and critical weight loss on overall survival in patients with hepatocellular carcinoma initially treated with chemoembolization. Gastroenterol Rep (Oxf) 2020;8:125-33. [PMID: 32280472 DOI: 10.1093/gastro/goz040] [Reference Citation Analysis]
329 Huang CF, Jang TY, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, Yu ML. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver Int 2021. [PMID: 34687130 DOI: 10.1111/liv.15085] [Reference Citation Analysis]
330 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
331 Guarino M, Caporaso N, Morisco F. Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy. Ann Transl Med 2020;8:1282. [PMID: 33209862 DOI: 10.21037/atm-20-6004] [Reference Citation Analysis]
332 Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72:288-306. [PMID: 31954493 DOI: 10.1016/j.jhep.2019.09.026] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 48.0] [Reference Citation Analysis]
333 Ahn SJ, Kim JH, Park SJ, Kim ST, Han JK. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict early recurrence after curative resection using image features and texture analysis.Abdom Radiol (NY). 2019;44:539-548. [PMID: 30229421 DOI: 10.1007/s00261-018-1768-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
334 Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
335 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
336 Chen CP. Role of Radiotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Transl Hepatol. 2019;7:183-190. [PMID: 31293919 DOI: 10.14218/jcth.2018.00060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
337 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
338 Choi MH, Choi JI, Lee YJ. Manual versus automated image fusion of real-time ultrasonography and MR/CT images for radiofrequency ablation of hepatic tumors: results of a randomized prospective trial (NCT02705118). Ultrasonography 2021;40:237-47. [PMID: 32660211 DOI: 10.14366/usg.20052] [Reference Citation Analysis]
339 Zhu G, Song J, Chen W, Yuan D, Wang W, Chen X, Liu H, Su H, Zhu J. Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. Cancer Manag Res 2021;13:659-75. [PMID: 33536782 DOI: 10.2147/CMAR.S275172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
340 Liu X, Gao H, Zhang J, Xue D. FAM83D is associated with gender, AJCC stage, overall survival and disease-free survival in hepatocellular carcinoma. Biosci Rep 2019;39:BSR20181640. [PMID: 30910840 DOI: 10.1042/BSR20181640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
341 Wang P, Zhang D, Fang C, Gan Y, Luo B, Yang XL, Peng FY, Li B, Su S. Partial hepatectomy vs. transcatheter arterial chemoembolization for multiple hepatocellular carcinomas of BCLC-B stage: A meta-analysis of high-quality studies. Eur J Surg Oncol 2022:S0748-7983(22)00412-7. [PMID: 35545472 DOI: 10.1016/j.ejso.2022.04.017] [Reference Citation Analysis]
342 Cao L, Cheng H, Jiang Q, Li H, Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging (Albany NY). 2020;12:4573-4591. [PMID: 32167932 DOI: 10.18632/aging.102913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
343 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
344 Kang N, Chung JW, Jang ES, Jeong SH, Kim JW. Computed Tomography-Measured Liver Volume Predicts the Risk of Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients. Dig Dis Sci 2021. [PMID: 33630218 DOI: 10.1007/s10620-020-06762-w] [Reference Citation Analysis]
345 Shi J, Chen L, Chen Y, Lu Y, Chen X, Yang Z. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. J Cancer 2019;10:4892-901. [PMID: 31598161 DOI: 10.7150/jca.32768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
346 Li B, Huang H, Huang R, Zhang W, Zhou G, Wu Z, Lv C, Han X, Jiang L, Li Y, Li B, Zhang Z. SEPT9 Gene Methylation as a Noninvasive Marker for Hepatocellular Carcinoma. Dis Markers 2020;2020:6289063. [PMID: 33178361 DOI: 10.1155/2020/6289063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
347 Lu Z, Chang L, Zhou H, Liu X, Li Y, Mi T, Tong D. Arctigenin Attenuates Tumor Metastasis Through Inhibiting Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma via Suppressing GSK3β-Dependent Wnt/β-Catenin Signaling Pathway In Vivo and In Vitro. Front Pharmacol 2019;10:937. [PMID: 31555129 DOI: 10.3389/fphar.2019.00937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
348 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
349 Hughes DM, Berhane S, Emily de Groot CA, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kolamunage-Dona R, Amoros R, Bird T, Garcίa-Fiñana M, Johnson P. Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2021;19:162-170.e4. [PMID: 32389887 DOI: 10.1016/j.cgh.2020.04.084] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
350 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
351 Xu W, Li R, Liu F. Novel Prognostic Nomograms for Predicting Early and Late Recurrence of Hepatocellular Carcinoma After Curative Hepatectomy. Cancer Manag Res. 2020;12:1693-1712. [PMID: 32214844 DOI: 10.2147/cmar.s241959] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
352 Feng B, Zhu Y, Sun C, Su Z, Tang L, Li C, Zheng G. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition. Int J Biol Macromol 2019;137:32-44. [PMID: 31252022 DOI: 10.1016/j.ijbiomac.2019.06.189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
353 Wu CH, Kao JH. Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria". Hepatol Int 2022. [PMID: 35088387 DOI: 10.1007/s12072-021-10272-w] [Reference Citation Analysis]
354 Funaoka A, Numata K, Takeda A, Saigusa Y, Tsurugai Y, Nihonmatsu H, Chuma M, Fukuda H, Okada M, Nakano M, Maeda S. Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. Diagnostics (Basel) 2021;11:486. [PMID: 33803373 DOI: 10.3390/diagnostics11030486] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Kim YY, Park MS, Aljoqiman KS, Choi JY, Kim MJ. Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. Clin Mol Hepatol 2019;25:223-33. [PMID: 30661336 DOI: 10.3350/cmh.2018.0107] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
356 Fraquelli M, Nadarevic T, Giljaca V, Colli A, Miletic D, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Contrast-enhanced ultrasound for the diagnosis of hepatocellular carcinoma in advanced chronic liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013483] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
357 Narsinh KH, Duncan DP, Newton IG, Minocha J, Rose SC. Liver-directed therapy for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:203-217. [PMID: 29230556 DOI: 10.1007/s00261-017-1435-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
358 Chan HLY, Vogel A, Berg T, De Toni EN, Kudo M, Trojan J, Eiblmaier A, Klein H, Hegel JK, Sharma A, Madin K, Rolny V, Lisy M, Piratvisuth T. Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis. JGH Open. [DOI: 10.1002/jgh3.12720] [Reference Citation Analysis]
359 Leoni S, Sansone V, Lorenzo S, Ielasi L, Tovoli F, Renzulli M, Golfieri R, Spinelli D, Piscaglia F. Treatment of Combined Hepatocellular and Cholangiocarcinoma. Cancers (Basel) 2020;12:E794. [PMID: 32224916 DOI: 10.3390/cancers12040794] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
360 Hu S, Wu X, Wei M, Ling Y, Zhu M, Wang Y, Chen Y, Jin M, Peng Z. Cost-Effectiveness Analysis of Follow-Up Schedule for Hepatocellular Carcinoma after Radiofrequency Ablation. J Oncol 2022;2022:3569644. [PMID: 35345515 DOI: 10.1155/2022/3569644] [Reference Citation Analysis]
361 You Z, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, Peng X. P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization. J Cell Mol Med 2021;25:9168-82. [PMID: 34510715 DOI: 10.1111/jcmm.16792] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients. Clin Transl Gastroenterol 2021;12:e00310. [PMID: 33605612 DOI: 10.14309/ctg.0000000000000310] [Reference Citation Analysis]
363 Hu K, Yuan J, Tang B, Zhang F, Lu S, Chen R, Zhang L, Ren Z, Yin X. Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. Ann Transl Med 2021;9:237. [PMID: 33708864 DOI: 10.21037/atm-20-3118] [Reference Citation Analysis]
364 Li YC, Chen PH, Yeh JH, Hsiao P, Lo GH, Tan T, Cheng PN, Lin HY, Chen YS, Hsieh KC, Hsieh PM, Lin CW. Clinical outcomes of surgical resection versus radiofrequency ablation in very-early-stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2021;21:418. [PMID: 34749663 DOI: 10.1186/s12876-021-01995-z] [Reference Citation Analysis]
365 Tateishi R, Fujiwara N. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 195-224. [DOI: 10.1007/978-3-030-21540-8_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
366 Ueno Y. New generation cancer therapy: right direction for sure with some uncertainty. Hepatol Int 2019;13:22-4. [PMID: 30406337 DOI: 10.1007/s12072-018-9904-8] [Reference Citation Analysis]
367 Chang JW, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Seo YS, Lee HA, Kim MN, Lee YR, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Park SY, Kim SU. Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir. J Viral Hepat 2021;28:95-104. [DOI: 10.1111/jvh.13411] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
368 Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol 2020;30:5650-62. [PMID: 32409860 DOI: 10.1007/s00330-020-06911-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
369 Wu H, Liu T, Qi J, Qin C, Zhu Q. Four Autophagy-Related lncRNAs Predict the Prognosis of HCC through Coexpression and ceRNA Mechanism. Biomed Res Int 2020;2020:3801748. [PMID: 33102579 DOI: 10.1155/2020/3801748] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
370 Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, Yu ML. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. Hepatol Int 2021;15:946-56. [PMID: 34008091 DOI: 10.1007/s12072-021-10169-8] [Reference Citation Analysis]
371 Khanna R, Verma SK. Pediatric hepatocellular carcinoma. World J Gastroenterol 2018; 24(35): 3980-3999 [PMID: 30254403 DOI: 10.3748/wjg.v24.i35.3980] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
372 Ding J, Sun H, Xin Y, Li D. Metastatic hepatocellular carcinoma mimicking acute dacryocystitis. Canadian Journal of Ophthalmology 2018;53:e132-4. [DOI: 10.1016/j.jcjo.2017.10.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
373 Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
374 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
375 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
376 Tani J, Senoh T, Moriya A, Ogawa C, Deguchi A, Sakamoto T, Takuma K, Nakahara M, Oura K, Tadokoro T, Mimura S, Fujita K, Yoneyama H, Kobara H, Morishita A, Himoto T, Tsutsui A, Nagano T, Takaguchi K, Masaki T. Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers (Basel) 2021;13:2257. [PMID: 34066708 DOI: 10.3390/cancers13092257] [Reference Citation Analysis]
377 Liu B, Liu ZZ, Zhou ML, Lin JW, Chen XM, Li Z, Gao WB, Yu ZD, Liu T. Development of cMETspecific chimeric antigen receptorengineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells. Mol Med Rep. 2019;20:2823-2831. [PMID: 31524233 DOI: 10.3892/mmr.2019.10529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
378 Hur MH, Lee JH, Kim JY, Hong JH, Park MK, Cho HJ, Choi NR, Kim J, Kim MA, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee DH, Lee JM, Hong SK, Yi NJ, Lee KW, Suh KS, Yoon JH. Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:6009. [PMID: 34885118 DOI: 10.3390/cancers13236009] [Reference Citation Analysis]
379 Nadarevic T, Giljaca V, Colli A, Fraquelli M, Casazza G, Miletic D, Štimac D. Computed tomography for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;10:CD013362. [PMID: 34611889 DOI: 10.1002/14651858.CD013362.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
380 Ronot M, Purcell Y, Vilgrain V. Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. Dig Dis Sci 2019;64:934-50. [DOI: 10.1007/s10620-019-05547-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
381 Semmler G, Meyer EL, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, Bauer D, Chromy D, Simbrunner B, Scheiner B, Stättermayer AF, Pinter M, Schöfl R, Russo FP, Greenfield H, Schwarz M, Schwarz C, Gschwantler M, Alonso López S, Manzano ML, Ahumada A, Bañares R, Pons M, Rodriguez-Tajes S, Genesca J, Lens S, Trauner M, Ferenci P, Reiberger T, Mandorfer M. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. J Hepatol 2021:S0168-8278(21)02234-0. [PMID: 34871626 DOI: 10.1016/j.jhep.2021.11.025] [Reference Citation Analysis]
382 Xu X, Sun S, Liu Q, Liu X, Wu F, Shen C. Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY) 2022. [PMID: 35267069 DOI: 10.1007/s00261-022-03473-w] [Reference Citation Analysis]
383 Li J, Xing J, Yang Y, Liu J, Wang W, Xia Y, Yan Z, Wang K, Wu D, Wu L, Wan X, Yang T, Gao C, Si A, Wang H, Wu M, Lau WY, Chen Z, Shen F. Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2020;5:548-60. [PMID: 32164877 DOI: 10.1016/S2468-1253(19)30422-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
384 Liu B, Zhu X, Gao S, Guo J, Wang X, Cao G, Zhu L, Liu P, Xu H, Chen H, Zhang X, Liu S, Kou F. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma. J Interv Med 2019;2:91-6. [PMID: 34805879 DOI: 10.1016/j.jimed.2019.07.006] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
385 Wang F, Numata K, Nihonmatsu H, Chuma M, Moriya S, Nozaki A, Ogushi K, Fukuda H, Ruan L, Okada M, Luo W, Koizumi N, Nakano M, Otani M, Inayama Y, Maeda S. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. Int J Hyperthermia 2020;37:1149-58. [PMID: 32996799 DOI: 10.1080/02656736.2020.1825837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
386 Zhou Y, Ouyang J, Wang Z, Chen X, Zhu R, Li Q, Zhou J. A novel internal cold circulation radiofrequency-assisted device for liver transection. Int J Hyperthermia 2021;38:308-15. [PMID: 33627010 DOI: 10.1080/02656736.2021.1889046] [Reference Citation Analysis]
387 Sevco TJ, Masch WR, Maturen KE, Mendiratta-Lala M, Wasnik AP, Millet JD. Ultrasound (US) LI-RADS: Outcomes of Category US-3 Observations. AJR Am J Roentgenol 2021;217:644-50. [PMID: 34259543 DOI: 10.2214/AJR.20.23447] [Reference Citation Analysis]
388 Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
390 Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci 2020;21:E6757. [PMID: 32942580 DOI: 10.3390/ijms21186757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ikeda N, Aizawa N, Nishimura T, Iijima H, Nishiguchi S. Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2020;10:E238. [PMID: 32325995 DOI: 10.3390/diagnostics10040238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
392 Leeming DJ, Nielsen SH, Vongsuvanh R, Uchila P, Nielsen MJ, Reese-Petersen AL, van der Poorten D, Eslam M, Schuppan D, Karsdal MA, George J. Endotrophin, a pro-peptide of Type VI collagen, is a biomarker of survival in cirrhotic patients with hepatocellular carcinoma. Hepat Oncol 2020;8:HEP32. [PMID: 34084451 DOI: 10.2217/hep-2020-0030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
393 Mohammed FA, Elkady AI, Syed FQ, Mirza MB, Hakeem KR, Alkarim S. Anethum graveolens (dill) – A medicinal herb induces apoptosis and cell cycle arrest in HepG2 cell line. Journal of Ethnopharmacology 2018;219:15-22. [DOI: 10.1016/j.jep.2018.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
394 Zhou Y, Hu C, Yuan G, Liu J, Ren Y, Tang C, Yang S, Dai L, Li Y, Yang D. [Antiviral and antifibrotic therapies reduce occurrence of hepatocellular carcinoma in patients with chronic hepatitis B and liver fibrosis: a 144-week prospective cohort study]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:633-40. [PMID: 31270040 DOI: 10.12122/j.issn.1673-4254.2019.06.02] [Reference Citation Analysis]
395 Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 2020;30:2302-11. [DOI: 10.1007/s00330-019-06546-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
396 Liu Z, Liu Y, Zhang W, Hong Y, Meng J, Wang J, Zheng S, Xu X. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. [DOI: 10.1007/s12072-022-10321-y] [Reference Citation Analysis]
397 Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Can the Entire Ablative Hyperechoic Zone be Regarded as a Necrotic Lesion After Radiofrequency Ablation of the Liver? Ultrasound Med Biol 2021;47:2930-5. [PMID: 34266681 DOI: 10.1016/j.ultrasmedbio.2021.05.004] [Reference Citation Analysis]
398 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 70] [Article Influence: 25.7] [Reference Citation Analysis]
399 Zhang Y, Zhang J, Chen X, Yang Z. Polymeric immunoglobulin receptor (PIGR) exerts oncogenic functions via activating ribosome pathway in hepatocellular carcinoma. Int J Med Sci 2021;18:364-71. [PMID: 33390805 DOI: 10.7150/ijms.49790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
400 Lee TH, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, Ronald J. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR-TR Lesions. Dig Dis Sci 2022. [PMID: 35257246 DOI: 10.1007/s10620-022-07428-5] [Reference Citation Analysis]
401 Lu W, Tang H, Yang Z, Jiang K, Chen Y, Lu S. Clinical predictors of small solitary hepatitis B virus-related hepatocellular carcinoma microinvasion. ANZ J Surg 2019;89:E438-42. [PMID: 31508888 DOI: 10.1111/ans.15403] [Reference Citation Analysis]
402 Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, Lau DTY. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 216-229 [DOI: 10.3748/wjg.v28.i2.216] [Reference Citation Analysis]
403 Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents. J Gastroenterol 2022. [PMID: 35031857 DOI: 10.1007/s00535-021-01837-5] [Reference Citation Analysis]
404 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
405 Dunn R, Wetten A, McPherson S, Donnelly MC. Viral hepatitis in 2021: The challenges remaining and how we should tackle them. World J Gastroenterol 2022; 28(1): 76-95 [DOI: 10.3748/wjg.v28.i1.76] [Reference Citation Analysis]
406 Park Y, Han Y, Kim D, Cho S, Kim W, Hwang H, Lee HW, Han DH, Kim KS, Yun M, Lee M. Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells. Cancers 2022;14:1205. [DOI: 10.3390/cancers14051205] [Reference Citation Analysis]
407 Campion D, Tucci A, Ponzo P, Caviglia GP. Non-invasive biomarkers for the detection of hepatocellular carcinoma. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.18.02488-6] [Cited by in Crossref: 13] [Article Influence: 4.3] [Reference Citation Analysis]
408 Mai R, Zeng J, Lu H, Liang R, Lin Y, Piao X, Gao X, Wu G, Wu F, Ma L, Xiang B, Li L, Ye J. Combining Aspartate Aminotransferase-to-Platelet Ratio Index with Future Liver Remnant to Assess Preoperative Hepatic Functional Reserve in Patients with Hepatocellular Carcinoma. J Gastrointest Surg 2021;25:688-97. [DOI: 10.1007/s11605-020-04575-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
409 Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol 2020;30:4150-63. [PMID: 32166493 DOI: 10.1007/s00330-020-06754-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
410 Hsiao CY, Hu RH, Ho CM, Wu YM, Lee PH, Ho MC. Surgical resection versus radiofrequency ablation for Barcelona Clinic Liver Cancer very early stage hepatocellular carcinoma: long-term results of a single-center study. Am J Surg 2020;220:958-64. [PMID: 32247523 DOI: 10.1016/j.amjsurg.2020.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
411 Liu M, Shi J, Mou T, Wang Y, Wu Z, Shen A. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol Hepatol. 2020;35:1277-1287. [PMID: 32052876 DOI: 10.1111/jgh.15010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
412 Qi YP, Zhong JH, Liang ZY, Zhang J, Chen B, Chen CZ, Li LQ, Xiang BD. Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion. Am J Surg. 2019;217:739-744. [PMID: 30103903 DOI: 10.1016/j.amjsurg.2018.07.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
413 Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;:101799. [PMID: 34500120 DOI: 10.1016/j.clinre.2021.101799] [Reference Citation Analysis]
414 Liu L, Li NF, Zhang Q, Lin L. Hepatocellular carcinoma successfully treated with ALPPS and apatinib: A case report. World J Clin Cases 2019; 7(16): 2384-2392 [PMID: 31531335 DOI: 10.12998/wjcc.v7.i16.2384] [Reference Citation Analysis]
415 Ryu T, Takami Y, Wada Y, Hara T, Sasaki S, Saitsu H. Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma ≤5 cm: A propensity score-matched analysis. Surgery 2019;166:254-62. [PMID: 31279438 DOI: 10.1016/j.surg.2019.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
416 Piratvisuth T, Tanwandee T, Thongsawat S, Sukeepaisarnjaroen W, Esteban JI, Bes M, Köhler B, He Y, Swiatek-de Lange M, Morgenstern D, Chan HL. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study. Hepatol Commun 2021. [PMID: 34796691 DOI: 10.1002/hep4.1847] [Reference Citation Analysis]
417 Li J, Ling W, Chen S, Ma L, Yang L, Lu Q, Luo Y. The interreader agreement and validation of contrast-enhanced ultrasound liver imaging reporting and data system. European Journal of Radiology 2019;120:108685. [DOI: 10.1016/j.ejrad.2019.108685] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
418 Haubold J, Ludwig JM, Li Y, Buechter M, Wetter A, Umutlu L, Theysohn JM. Measuring the density of iodine depositions: Detecting an invisible residual tumor after conventional transarterial chemoembolization. PLoS One 2020;15:e0227972. [PMID: 31995589 DOI: 10.1371/journal.pone.0227972] [Reference Citation Analysis]
419 Zhang XY, Ou J, Chen JY, Li WW. Predicting early hepatocellular carcinoma recurrence after resection: A comment for moving forward. J Hepatol 2019;70:567-8. [PMID: 30554930 DOI: 10.1016/j.jhep.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
420 Chang YJ, Chen LJ, Chang YJ, Chen PD. Population-based matching comparison between radiofrequency ablation and percutaneous ethanol or acetic acid injection for hepatocellular carcinoma. Eur J Surg Oncol 2020;46:1703-10. [PMID: 32475629 DOI: 10.1016/j.ejso.2020.04.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
421 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
422 Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, Toyoda H, Nouso K, Joko K, Hiasa Y, Michitaka K, Kudo M. Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer 2019;8:121-9. [PMID: 31019902 DOI: 10.1159/000488778] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 11.3] [Reference Citation Analysis]
423 Kaibori M, Matsushima H, Ishizaki M, Kosaka H, Matsui K, Kariya S, Yoshii K, Sekimoto M. The Impact of Sorafenib in Combination with Transarterial Chemoembolization on the Outcomes of Intermediate-Stage Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2021;22:1217-24. [PMID: 33906315 DOI: 10.31557/APJCP.2021.22.4.1217] [Reference Citation Analysis]
424 Qiu L, Zhan K, Malale K, Wu X, Mei Z. Transcriptomic profiling of peroxisome-related genes reveals a novel prognostic signature in hepatocellular carcinoma. Genes & Diseases 2020. [DOI: 10.1016/j.gendis.2020.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
425 Yu SCH. Blood Flow Diversion Within Hepatocellular Carcinoma (HCC) after Selective Occlusion of Feeding Arteries (SOFA) and Feasibility of Utilizing the SOFA Technique in Transarterial Chemoembolization (SOFA-TACE). Cardiovasc Intervent Radiol 2021. [PMID: 34604919 DOI: 10.1007/s00270-021-02973-4] [Reference Citation Analysis]
426 Ji M, Liu Z, Chang ET, Yu X, Wu B, Deng L, Feng Q, Wei K, Liang X, Lian S, Quan W, Wang P, Du Y, Liang Z, Xia S, Lin H, Li F, Cheng W, Chen W, Yuan Y, Ye W. Mass screening for liver cancer: results from a demonstration screening project in Zhongshan City, China. Sci Rep 2018;8:12787. [PMID: 30143694 DOI: 10.1038/s41598-018-31119-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
427 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
428 Shao YY, Wang SY, Lin SM; Diagnosis Group,., Systemic Therapy Group. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc 2021;120:1051-60. [PMID: 33199101 DOI: 10.1016/j.jfma.2020.10.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
429 Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist 2021;26:e367-73. [PMID: 33140457 DOI: 10.1002/onco.13582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
430 Liu YW, Yong CC, Lin CC, Wang CC, Chen CL, Cheng YF, Wang JH, Yen YH, Chen CH. Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. J Surg Oncol 2020;122:1587-94. [PMID: 32815189 DOI: 10.1002/jso.26183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
431 Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer 2019;19:795. [PMID: 31409405 DOI: 10.1186/s12885-019-5989-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
432 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
433 Kim HI, Jang JK, Lim J, Chang S, An J, Kang HJ, Song GW, Lee SG, Kim SY, Shim JH. Hepatocyte-Specific Magnetic Resonance Imaging-Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis. Liver Transpl 2020;26:359-69. [PMID: 31756026 DOI: 10.1002/lt.25684] [Reference Citation Analysis]
434 Finn RS. Searching for common ground in a global disease. Hepatobiliary Surg Nutr 2018;7:297-9. [PMID: 30221159 DOI: 10.21037/hbsn.2018.04.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
435 Alnammi M, Wortman J, Therrien J, Afnan J. MRI features of treated hepatocellular carcinoma following locoregional therapy: a pictorial review. Abdom Radiol (NY) 2022. [PMID: 35524803 DOI: 10.1007/s00261-022-03526-0] [Reference Citation Analysis]
436 Kim MN, Lee SM, Kim JS, Hwang SG. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemother Pharmacol 2019;84:809-17. [PMID: 31385002 DOI: 10.1007/s00280-019-03918-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
437 Kim DW, Choi SH, Kim SY, Byun JH, Lee SS, Park SH, Kim KW. Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 2020;14:1009-22. [DOI: 10.1007/s12072-020-10100-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
438 Khan AA, Hadi YB, Thompson JM, Kupec JT. Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis. BMJ Open Gastroenterol 2020;7:e000394. [PMID: 32398242 DOI: 10.1136/bmjgast-2020-000394] [Reference Citation Analysis]
439 Kiri L, Abdolell M, Costa AF, Keough V, Rowe J, Butt R, Clarke SE. US LI-RADS Visualization Score: Interobserver Variability and Association With Cause of Liver Disease, Sex, and Body Mass Index. Can Assoc Radiol J 2021;:8465371211012104. [PMID: 33938768 DOI: 10.1177/08465371211012104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
440 Hong WF, Gu YJ, Wang N, Xia J, Zhou HY, Zhan K, Cheng MX, Cai Y. Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:301-14. [PMID: 34221916 DOI: 10.14218/JCTH.2020.00132] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Guo H, Li P, Su L, Wu K, Huang K, Lai R, Xu J, Sun D, Li S, Deng Z, Wang Y, Guo H, Chen Z, Wang S. Low expression of IL-37 protein is correlated with high Oct4 protein expression in hepatocellular carcinoma. Gene 2020;737:144445. [PMID: 32035244 DOI: 10.1016/j.gene.2020.144445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
442 Min JH, Kim JM, Kim YK, Cha DI, Kang TW, Kim H, Choi GS, Choi S, Ahn S. Magnetic Resonance Imaging With Extracellular Contrast Detects Hepatocellular Carcinoma With Greater Accuracy Than With Gadoxetic Acid or Computed Tomography. Clinical Gastroenterology and Hepatology 2020;18:2091-2100.e7. [DOI: 10.1016/j.cgh.2019.12.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
443 Shao W, Li C, Tang J, Song J, Li Z, Sun J, Xu Y, Zheng Z, Cao J, Zhang L. Efficacy And Safety Of Raltitrexed Plus Oxaliplatin-Based Transarterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma. Cancer Manag Res 2019;11:9863-9. [PMID: 31819623 DOI: 10.2147/CMAR.S217524] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
444 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
445 Radu P, Dufour JF. Changing TACTICS in intermediate HCC: TACE plus sorafenib. Gut 2020;69:1374-6. [PMID: 32169908 DOI: 10.1136/gutjnl-2020-320692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
446 Zhu Z, Xu J, Wu X, Lin S, Li L, Ye W, Huang Z. In Silico Identification of Contradictory Role of ADAMTS5 in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:1533033820986826. [PMID: 33522433 DOI: 10.1177/1533033820986826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Peng C, Teng W, Hsieh Y, Jeng W, Huang C, Lui K, Hung C, Chen Y, Lin C, Lin C, Lin S, Sheen I. Postembolization fever after transarterial chemoembolization is a sign of unfavorable therapeutic response in hepatocellular carcinoma patients. Adv in Digestive Med 2020;7:83-92. [DOI: 10.1002/aid2.13182] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
448 Hui Y, Zeng H, Feng Y, Qin W, Chen P, Huang L, Zhong W, Lin L, Lv H, Qin X. Regulatory Role of SFN Gene in Hepatocellular Carcinoma and Its Mechanism. Biotechnol Bioproc E 2021;26:375-83. [DOI: 10.1007/s12257-020-0292-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
449 Chang WC, Hsu HH, Chiu SH, Huang WY, Lo CH, Lin HH, Huang PC, Shih YL, Wan YL. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads. J Hepatocell Carcinoma 2021;8:937-49. [PMID: 34422707 DOI: 10.2147/JHC.S319920] [Reference Citation Analysis]
450 Zhu WJ, Yan Y, Zhang JW, Tang YD, Han B. Effect and Mechanism of miR-26a-5p on Proliferation and Apoptosis of Hepatocellular Carcinoma Cells. Cancer Manag Res 2020;12:3013-22. [PMID: 32431544 DOI: 10.2147/CMAR.S237752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
451 Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [DOI: 10.1002/hep.31187] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
452 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
453 Liu X, Li M, Wang X, Dang Z, Yu L, Wang X, Jiang Y, Yang Z. Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma. Phytomedicine 2019;62:152930. [DOI: 10.1016/j.phymed.2019.152930] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
454 Maruyama H, Shiina S. Contrast-enhanced ultrasonography: is it an ideal tool for hepatocellular carcinoma surveillance? Quant Imaging Med Surg 2019;9:1611-4. [PMID: 31667146 DOI: 10.21037/qims.2019.08.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
455 Verde F, Ponsiglione A. Role of perfusion features in contrast-enhanced ultrasound differential diagnosis of hepatocellular adenoma and carcinoma: Far beyond the gray-scale ultrasound. J Clin Ultrasound 2022;50:222-3. [PMID: 35147999 DOI: 10.1002/jcu.23140] [Reference Citation Analysis]
456 Obi S, Sato T, Sato S, Kanda M, Tokudome Y, Kojima Y, Suzuki Y, Hosoda K, Kawai T, Kondo Y, Isomura Y, Ohyama H, Nakagomi K, Ashizawa H, Miura Y, Amano H, Mochizuki H, Omata M. The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in a real-world setting. Hepatol Int. 2019;13:199-204. [PMID: 30671808 DOI: 10.1007/s12072-019-09929-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
457 Chien SC, Chen CY, Cheng PN, Liu YS, Cheng HC, Chuang CH, Chang TT, Chiu HC, Lin YJ, Chiu YC. Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. Liver Cancer 2019;8:186-202. [PMID: 31192155 DOI: 10.1159/000489790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
458 Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2018; 10(7): 485-495 [PMID: 30079135 DOI: 10.4254/wjh.v10.i7.485] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
459 Chuon C, Takahashi K, Matsuo J, Katayama K, Yamamoto C, Ko K, Hok S, Nagashima S, Akbar SMF, Tanaka J. High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank. Sci Rep 2019;9:12186. [PMID: 31434918 DOI: 10.1038/s41598-019-48304-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
460 Ghiuchici AM, Sporea I, Dănilă M, Șirli R, Moga T, Bende F, Popescu A. Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma? J Clin Med 2021;10:1710. [PMID: 33921086 DOI: 10.3390/jcm10081710] [Reference Citation Analysis]
461 Kim DH, Choi SH, Lee JS, Choi JI. Inter-reader agreement of abbreviated magnetic resonance imaging for hepatocellular carcinoma detection: a systematic review and meta-analysis. Abdom Radiol (NY) 2021. [PMID: 34633497 DOI: 10.1007/s00261-021-03297-0] [Reference Citation Analysis]
462 Cho YY, Yu SJ, Lee HW, Kim DY, Kang W, Paik YH, Sung PS, Bae SH, Park SC, Doh YS, Kim KM, Jang ES, Kim IH, Kim W, Kim YJ. Clinical Characteristics of Long-Term Survivors After Sorafenib Treatment for Unresectable Hepatocellular Carcinoma: A Korean National Multicenter Retrospective Cohort Study. J Hepatocell Carcinoma 2021;8:613-23. [PMID: 34169044 DOI: 10.2147/JHC.S304439] [Reference Citation Analysis]
463 Yu GI, Mun KH, Yang SH, Shin DH, Hwang JS. Polymorphisms in the 3'-UTR of SCD5 gene are associated with hepatocellular carcinoma in Korean population. Mol Biol Rep 2018;45:1705-14. [PMID: 30168096 DOI: 10.1007/s11033-018-4313-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
464 Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, Kanatsiz E, Kiyak M, Ozdil K, Doganay HL. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment. World J Gastroenterol 2022; 28(6): 665-674 [DOI: 10.3748/wjg.v28.i6.665] [Reference Citation Analysis]
465 Yoon YI, Lee SG. Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective. Dig Dis Sci 2019;64:993-1000. [PMID: 30895483 DOI: 10.1007/s10620-019-05551-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
466 Kim JG, Cho SK, Hyun D, Shin SW, Park KB, Park HS, Choo SW, Do YS, Woo SY, Baek SY. Combined transarterial chemoembolization and radiofrequency ablation for subphrenic versus nonsubphrenic hepatocellular carcinoma: a propensity score matched study. Abdom Radiol (NY) 2021;46:5735-45. [PMID: 34581928 DOI: 10.1007/s00261-021-03291-6] [Reference Citation Analysis]
467 Liu Z, Zhang Z, Mei H, Mao J, Zhou X. Distribution and clinical relevance of phospholipids in hepatocellular carcinoma. Hepatol Int 2020;14:544-55. [PMID: 32504407 DOI: 10.1007/s12072-020-10056-8] [Reference Citation Analysis]
468 Huang CF, Wang SC, Chang WT, Yeh ML, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Chen YL, Yu ML. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. Sci Rep 2018;8:15821. [PMID: 30361527 DOI: 10.1038/s41598-018-34155-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
469 Jang TY, Wei YJ, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. J Gastroenterol Hepatol 2020;35:1886-92. [PMID: 32247291 DOI: 10.1111/jgh.15061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
470 Laube R, Sabih AH, Strasser SI, Lim L, Cigolini M, Liu K. Palliative care in hepatocellular carcinoma.J Gastroenterol Hepatol. 2021;36:618-628. [PMID: 32627853 DOI: 10.1111/jgh.15169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
471 Lai S, Lin C, Liao K. Synergistic effect of oral corticosteroids use on risk of hepatocellular carcinoma in high risk populations. European Journal of Internal Medicine 2018;52:73-7. [DOI: 10.1016/j.ejim.2018.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
472 Younes R, Bugianesi E. Should we undertake surveillance for HCC in patients with NAFLD? Journal of Hepatology 2018;68:326-34. [DOI: 10.1016/j.jhep.2017.10.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 19.0] [Reference Citation Analysis]
473 Tan DJH, Wong C, Ng CH, Poh CW, Jain SR, Huang DQ, Muthiah MD. A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity. J Clin Med 2021;10:E238. [PMID: 33440759 DOI: 10.3390/jcm10020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Wang DC, Jang H, Kim TK. Characterization of Indeterminate Liver Lesions on CT and MRI With Contrast-Enhanced Ultrasound: What Is the Evidence? American Journal of Roentgenology 2020;214:1295-304. [DOI: 10.2214/ajr.19.21498] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
475 Mukund A, Bhardwaj K, Choudhury A, Sarin SK. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm). Journal of Clinical and Experimental Hepatology 2021. [DOI: 10.1016/j.jceh.2021.02.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
476 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Combined Albumin-Bilirubin Grade and Skeletal Muscle Mass as a Predictor in Liver Cirrhosis. J Clin Med 2019;8:E782. [PMID: 31159435 DOI: 10.3390/jcm8060782] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
477 Kwon JW, Tchoe HJ, Lee J, Suh JK, Lee JH, Shin S. The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea. Gut Liver 2020;14:108-16. [PMID: 30974929 DOI: 10.5009/gnl18522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
478 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
479 Kamalapirat T, Yingcharoen K, Ungtrakul T, Soonklang K, Dechma J, Chunnuan P, Kusuman P, Pothijaroen C, Tawpa J, Cheirsilpa K, Auewarakul C. Assessing risk scores for predicting hepatocellular carcinoma in Thai patients with chronic hepatitis B. J Viral Hepat 2021;28:1034-41. [PMID: 33880807 DOI: 10.1111/jvh.13517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
480 Kedarisetty CK, Bal S, Parida S, Jain M, Bhadoria AS, Varghese J, Venkataraman J. Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. J Clin Exp Hepatol 2021;11:299-304. [PMID: 33994712 DOI: 10.1016/j.jceh.2020.10.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Di Tommaso L, Spadaccini M, Donadon M, Personeni N, Elamin A, Aghemo A, Lleo A. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol 2019; 25(40): 6041-6052 [PMID: 31686761 DOI: 10.3748/wjg.v25.i40.6041] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
482 Zhen SH, Cheng M, Tao YB, Wang YF, Juengpanich S, Jiang ZY, Jiang YK, Yan YY, Lu W, Lue JM, Qian JH, Wu ZY, Sun JH, Lin H, Cai XJ. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. Front Oncol. 2020;10:680. [PMID: 32547939 DOI: 10.3389/fonc.2020.00680] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
483 Du Y, Ma X, Wang D, Wang Y, Zhang T, Bai L, Liu Y, Chen S. Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma. J Gastrointest Oncol 2021;12:2361-76. [PMID: 34790398 DOI: 10.21037/jgo-21-468] [Reference Citation Analysis]
484 Liu J, Li Q, Shi N, Chen Y, Li Y, Zhang M, Huang Y. Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. JGH Open 2021;5:382-9. [PMID: 33732886 DOI: 10.1002/jgh3.12507] [Reference Citation Analysis]
485 Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. World J Gastroenterol 2020; 26(4): 393-403 [PMID: 32063688 DOI: 10.3748/wjg.v26.i4.393] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
486 Cassese G, Han H, Lee B, Lee HW, Cho JY, Troisi R. Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma. Cancers 2022;14:2012. [DOI: 10.3390/cancers14082012] [Reference Citation Analysis]
487 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
488 Zhou Y, Zhou X, Ma J, Zhang W, Yan Z, Luo J. Nomogram for Predicting the Prognosis of Patients with Hepatocellular Carcinoma Presenting with Pulmonary Metastasis. Cancer Manag Res 2021;13:2083-94. [PMID: 33688251 DOI: 10.2147/CMAR.S296020] [Reference Citation Analysis]
489 Lee CS, Jung YJ, Kim SS, Cheong JY, Lee GR, Kim HG, Kim BH, Chung JW, Jang ES, Jeong SH, Lee KH, Kim JW. Liver volume-based prediction model stratifies risks for hepatocellular carcinoma in chronic hepatitis B patients on surveillance. PLoS One 2018;13:e0190261. [PMID: 29293612 DOI: 10.1371/journal.pone.0190261] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
490 Endo K, Kuroda H, Oikawa T, Okada Y, Fujiwara Y, Abe T, Sato H, Sawara K, Takikawa Y. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma. Scand J Gastroenterol 2018;53:1575-83. [PMID: 30577723 DOI: 10.1080/00365521.2018.1548645] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
491 Bessar AA, Farag A, Abdel Monem SM, Wadea FM, Shaker SE, Ebada MA, Bessar MA. Transarterial chemoembolisation in patients with hepatocellular carcinoma: low-dose doxorubicin reduces post-embolisation syndrome without affecting survival-prospective interventional study. Eur Radiol Exp 2021;5:10. [PMID: 33649930 DOI: 10.1186/s41747-021-00204-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
492 Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. Biomed Res Int 2018;2018:7465126. [PMID: 30105242 DOI: 10.1155/2018/7465126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
493 Wang F, Numata K, Nihonmatsu H, Okada M, Maeda S. Application of new ultrasound techniques for focal liver lesions. J Med Ultrason (2001) 2020;47:215-37. [PMID: 31950396 DOI: 10.1007/s10396-019-01001-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
494 Nguyen ALT, Nguyen HTT, Yee KC, Palmer AJ, Blizzard CL, de Graaff B. A Systematic Review and Narrative Synthesis of Health Economic Evaluations of Hepatocellular Carcinoma Screening Strategies. Value Health 2021;24:733-43. [PMID: 33933243 DOI: 10.1016/j.jval.2020.11.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
495 Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. Cancer Med 2020;9:3057-69. [PMID: 32150664 DOI: 10.1002/cam4.2968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
496 Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol 2020;72:209-14. [PMID: 31954486 DOI: 10.1016/j.jhep.2019.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
497 Degasperi E, Perbellini R, D'Ambrosio R, Uceda Renteria SC, Ceriotti F, Perego A, Orsini C, Borghi M, Iavarone M, Bruccoleri M, Rimondi A, De Silvestri A, Sangiovanni A, Lampertico P. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents. Aliment Pharmacol Ther 2021. [PMID: 34738664 DOI: 10.1111/apt.16685] [Reference Citation Analysis]
498 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
499 Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, Yu ML. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int 2021;41:1265-77. [PMID: 33655714 DOI: 10.1111/liv.14849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
500 Al-salama ZT, Syed YY, Scott LJ. Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 2019;79:665-74. [DOI: 10.1007/s40265-019-01116-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
501 Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
503 Sun W, Zhang J, Chen J. MicroRNA-520a suppresses HBV replication in HepG2.2.15 cells by inactivating AKT. J Int Med Res 2018;46:4693-704. [PMID: 30191752 DOI: 10.1177/0300060518792780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
504 Saeki I, Yamasaki T, Maeda M, Hisanaga T, Iwamoto T, Fujisawa K, Matsumoto T, Hidaka I, Marumoto Y, Ishikawa T, Yamamoto N, Suehiro Y, Takami T, Sakaida I. Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy. World J Hepatol 2018; 10(9): 571-584 [PMID: 30310535 DOI: 10.4254/wjh.v10.i9.571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
505 Choi HH, Rodgers SK, Khurana A, Nelson LW, Kamaya A. Role of Ultrasound for Chronic Liver Disease and Hepatocellular Carcinoma Surveillance. Magn Reson Imaging Clin N Am 2021;29:279-90. [PMID: 34243917 DOI: 10.1016/j.mric.2021.05.005] [Reference Citation Analysis]
506 Qu M, Jia Z, Sun L, Wang H. Diagnostic accuracy of three-dimensional contrast-enhanced ultrasound for focal liver lesions: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e28147. [PMID: 34941062 DOI: 10.1097/MD.0000000000028147] [Reference Citation Analysis]
507 Deng M, Li SH, Guo RP. Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma. Am Surg 2021;:31348211054532. [PMID: 34743609 DOI: 10.1177/00031348211054532] [Reference Citation Analysis]
508 Chen Y, Yang Y, Li S, Lin M, Xie X, Shi H, Jiang Y, Zheng S, Shao H, Yang N, Lu M. Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients. Front Public Health 2022;9:784718. [DOI: 10.3389/fpubh.2021.784718] [Reference Citation Analysis]
509 Agnello F, Rabiolo L, Midiri F, Lo Re G, Grassedonio E, La Grutta L, Buscemi S, Agrusa A, Galia M. Focal hepatic intrinsically hyperattenuating lesions at unenhanced CT: Not always calcifications. Clin Imaging 2021;80:304-14. [PMID: 34482241 DOI: 10.1016/j.clinimag.2021.08.020] [Reference Citation Analysis]
510 Ballestri S, Nascimbeni F, Lugari S, Lonardo A, Francica G. A critical appraisal of the use of ultrasound in hepatic steatosis. Expert Rev Gastroenterol Hepatol 2019;13:667-81. [PMID: 31104523 DOI: 10.1080/17474124.2019.1621164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
511 Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, Zhou J, Gong J, Wang J, Wen X, Zhou T, Zhai X, Xu Q, Zhang T, Chen X, Hu G, Wang J, Gao Z, Nan Y, Chen J, Hu B, Zhao J, Lu F. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat 2021;28:20-9. [PMID: 32852885 DOI: 10.1111/jvh.13388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
512 Ao J, Chiba T, Shibata S, Kurosugi A, Qiang N, Ma Y, Kan M, Iwanaga T, Sakuma T, Kanzaki H, Kanayama K, Kojima R, Kusakabe Y, Nakamura M, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Muroyama R, Kato J, Mimura N, Kanda T, Maruyama H, Kato N. Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells. Biochem Biophys Res Commun 2021;549:171-8. [PMID: 33676186 DOI: 10.1016/j.bbrc.2021.02.097] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
513 Liu J, Xu R, Mai SJ, Ma YS, Zhang MY, Cao PS, Weng NQ, Wang RQ, Cao D, Wei W, Guo RP, Zhang YJ, Xu L, Chen MS, Zhang HZ, Huang L, Fu D, Wang HY. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling. Theranostics 2020;10:7527-44. [PMID: 32685003 DOI: 10.7150/thno.45989] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
514 Suceveanu AI, Micu IS, Baltatescu GI, Petcu LC, Dobrin N, Brinzan C, Nitipir C, Mazilu L, Botea F, Herlea V, Voinea F, Suceveanu AP. Overexpression of Survivin-1, TAG-72 and HERC5 in patients diagnosed with hepatocellular carcinoma in the Black Sea coast geographical area. Exp Ther Med 2021;21:284. [PMID: 33603891 DOI: 10.3892/etm.2021.9715] [Reference Citation Analysis]
515 Gill J, Baiceanu A, Clark PJ, Langford A, Latiff J, Yang PM, Yoshida EM, Kanavos P. Insights into the hepatocellular carcinoma patient journey: results of the first global quality of life survey. Future Oncol 2018;14:1701-10. [PMID: 29543521 DOI: 10.2217/fon-2017-0715] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
516 Li M, Sun F, Bi X, Lin Y, Yang L, Lu Y, Zhang L, Wan G, Yi W, Zhao L, Xie Y. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients. Virologica Sinica 2022. [DOI: 10.1016/j.virs.2022.03.001] [Reference Citation Analysis]
517 Nie G, Peng D, Li B, Lu J, Cai Y, Xiong X, Cheng N. Diagnostic Accuracy of Serum/Plasma Circular RNAs and the Combination of Circular RNAs and α-Fetoprotein for Detecting Hepatocellular Carcinoma: A Meta-Analysis. Front Genet 2021;12:722208. [PMID: 34659344 DOI: 10.3389/fgene.2021.722208] [Reference Citation Analysis]
518 Su F, Weiss NS, Beste LA, Moon AM, Jin GY, Green P, Berry K, Ioannou GN. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol 2021;74:850-9. [PMID: 33245934 DOI: 10.1016/j.jhep.2020.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
519 Zhao X, Hao J, Chen S. Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer. Evid Based Complement Alternat Med 2020;2020:6076572. [PMID: 32256653 DOI: 10.1155/2020/6076572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Kariyama K, Nouso K, Wakuta A, Oonishi A, Toyoda H, Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. Liver Cancer 2020;9:41-9. [PMID: 32071908 DOI: 10.1159/000502479] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
521 Huo YR, Chan MV, Chan C. Resection Plus Post-operative Adjuvant Transcatheter Arterial Chemoembolization (TACE) Compared with Resection Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2020;43:572-86. [PMID: 31897617 DOI: 10.1007/s00270-019-02392-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
522 Shiba S, Shibuya K, Katoh H, Kaminuma T, Miyazaki M, Kakizaki S, Shirabe K, Ohno T, Nakano T. A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study. Radiat Oncol 2019;14:137. [PMID: 31375120 DOI: 10.1186/s13014-019-1347-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
523 Wang JH, Li WF, Yong CC, Liu YW, Lu SN, Wang CC. Liver stiffness and insulin resistance in predicting recurrence for early stage hepatoma patients after curative resection. Sci Rep 2021;11:6041. [PMID: 33723365 DOI: 10.1038/s41598-021-85431-y] [Reference Citation Analysis]
524 Yongpisarn T, Thimphitthaya C, Laoveeravat P, Wongjarupong N, Chaiteerakij R. Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis. World J Hepatol 2021; 13(8): 949-968 [PMID: 34552701 DOI: 10.4254/wjh.v13.i8.949] [Reference Citation Analysis]
525 Lang S, Martin A, Kasper P, Schramm C, Kütting F, Goeser T, Steffen HM, Demir M. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol 2020;55:222-7. [PMID: 31990240 DOI: 10.1080/00365521.2020.1718747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
526 An J. [Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis]. Korean J Gastroenterol 2021;78:255-60. [PMID: 34824183 DOI: 10.4166/kjg.2021.142] [Reference Citation Analysis]
527 Pan J, Li W, Gu L, Liu C, Zhang K, Hong G. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis. Eur Radiol 2022. [PMID: 35579711 DOI: 10.1007/s00330-022-08826-z] [Reference Citation Analysis]
528 Liu KC, Lv WF, Lu D, Hou CL, Xie J, Lu YH, Cao QS, Tan YL, Zhang YZ, Liu J. Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma. Cancer Manag Res 2021;13:7973-80. [PMID: 34703317 DOI: 10.2147/CMAR.S332571] [Reference Citation Analysis]
529 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
530 Kim TM, Lee JM, Yoon JH, Joo I, Park SJ, Jeon SK, Schmidt B, Martin S. Prediction of microvascular invasion of hepatocellular carcinoma: value of volumetric iodine quantification using preoperative dual-energy computed tomography. Cancer Imaging 2020;20:60. [PMID: 32811570 DOI: 10.1186/s40644-020-00338-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
531 Byun J, Choi SH, Byun JH, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 2020;14:534-43. [PMID: 32314171 DOI: 10.1007/s12072-020-10040-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
532 Yim JH, Kim YK, Min JH, Lee J, Kang TW, Lee SJ. Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI. Abdom Radiol 2019;44:2366-76. [DOI: 10.1007/s00261-019-01968-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
533 Kamarajah SK. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): A Surveillance, End Results and Epidemiology (SEER) database analysis. Asian Journal of Surgery 2018;41:551-61. [DOI: 10.1016/j.asjsur.2018.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
534 Bae JS, Lee JM, Jeon SK, Jang S. Comparison of MicroFlow Imaging with color and power Doppler imaging for detecting and characterizing blood flow signals in hepatocellular carcinoma.Ultrasonography. 2020;39:85-93. [PMID: 31759383 DOI: 10.14366/usg.19033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
535 Feng Z, Zhao H, Guan S, Wang W, Rong P. Diagnostic performance of MRI using extracellular contrast agents versus gadoxetic acid for hepatocellular carcinoma: A systematic review and meta‐analysis. Liver Int 2021;41:1117-28. [DOI: 10.1111/liv.14850] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
536 Xiao H, Li JL, Chen SL, Tang MM, Zhou Q, Wu TF, Li X, Peng ZW, Feng ST, Peng S, Kuang M. A Pre-Operative Prognostic Score for Patients With Advanced Hepatocellular Carcinoma Who Underwent Resection. Front Oncol 2021;11:569515. [PMID: 33718130 DOI: 10.3389/fonc.2021.569515] [Reference Citation Analysis]
537 Chong CC, Chan AW, Wong J, Chu CM, Chan SL, Lee KF, Yu SC, To KF, Johnson P, Lai PB. Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Surgeon. 2018;16:163-170. [PMID: 28807570 DOI: 10.1016/j.surge.2017.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
538 Zhou N, Li S, Wu D, Zhang F, Tang F, Li Y. The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis. DNA Cell Biol 2021;40:1278-89. [PMID: 34558987 DOI: 10.1089/dna.2021.0235] [Reference Citation Analysis]
539 Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M. Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability. Hepatol Res 2020;50:67-74. [PMID: 31301213 DOI: 10.1111/hepr.13407] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
540 Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Sacco R, Cabibbo G, Virdone R, Marra F, Felder M, Morisco F, Benvegnù L, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Missale G, Masotto A, Nardone G, Colecchia A, Bernardi M, Trevisani F, Cillo U. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study. Liver Int 2019;39:1478-89. [PMID: 31131974 DOI: 10.1111/liv.14154] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
541 Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69:1492-501. [PMID: 31801872 DOI: 10.1136/gutjnl-2019-318934] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 20.7] [Reference Citation Analysis]
542 Wu G, Wu J, Pan X, Liu B, Yao Z, Guo Y, Shi X, Ding Y. Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients. Cancer Med. 2019;8:6614-6623. [PMID: 31517445 DOI: 10.1002/cam4.2549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
543 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
544 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
545 Cao Q, Lu W, Zhou T, Liu Y, Cai X, Zhu J, Cao P. Analgesic-antitumor peptide inhibits angiogenesis by suppressing AKT activation in hepatocellular carcinoma. Mol Cell Biochem 2019;455:119-25. [PMID: 30535530 DOI: 10.1007/s11010-018-3475-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
546 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
547 Zakir U, Siddiqui NN, Naqvi FU, Khan R. Aberrant STAT1 methylation as a non-invasive biomarker in blood of HCV induced hepatocellular carcinoma. Cancer Biomark 2021. [PMID: 34657877 DOI: 10.3233/CBM-210216] [Reference Citation Analysis]
548 Hung YW, Lee IC, Chi CT, Lee RC, Liu CA, Chiu NC, Hwang HE, Chao Y, Hou MC, Huang YH. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer 2021;10:629-40. [PMID: 34950185 DOI: 10.1159/000517393] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Shu Z, Gao F, Xia Q, Zhang M. MiR-9-5p promotes cell proliferation and migration of hepatocellular carcinoma by targeting CPEB3. Biomark Med 2021;15:97-108. [PMID: 33496636 DOI: 10.2217/bmm-2020-0322] [Reference Citation Analysis]
550 Ezzat R, Eltabbakh M, El Kassas M. Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures. World J Gastrointest Oncol 2021; 13(12): 1919-1938 [DOI: 10.4251/wjgo.v13.i12.1919] [Reference Citation Analysis]
551 Deng LX, Mehta N. Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers. Dig Dis Sci 2020;65:3456-62. [PMID: 32860090 DOI: 10.1007/s10620-020-06550-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
552 Su Y, You Y, Zeng Q, Tan L, Ye H, Liu J, Zheng R, Li K. Transcholecystic Contrast-Enhanced Ultrasound-Guided Percutaneous Transhepatic Biliary Drainage for Central Bile Duct Protection During Thermal Tumor Ablation. J Vasc Interv Radiol 2020;31:1587-91. [PMID: 32951970 DOI: 10.1016/j.jvir.2020.05.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
553 Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
554 Zhang Y, Chen X, Cao Y, Yang Z. C8B in Complement and Coagulation Cascades Signaling Pathway is a predictor for Survival in HBV-Related Hepatocellular Carcinoma Patients. Cancer Manag Res 2021;13:3503-15. [PMID: 33911900 DOI: 10.2147/CMAR.S302917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
555 Shen Y, Huang C, Zhu X, Xu M, Chen Z, Tan C, Zhou J, Fan J, Sun H. The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma. Annals of Surgery Open 2022;3:e163. [DOI: 10.1097/as9.0000000000000163] [Reference Citation Analysis]
556 Mir IH, Jyothi KC, Thirunavukkarasu C. The prominence of potential biomarkers in the diagnosis and management of hepatocellular carcinoma: Current scenario and future anticipation. J Cell Biochem 2021. [PMID: 34897788 DOI: 10.1002/jcb.30190] [Reference Citation Analysis]
557 Chen J, Wang Z, Ding Y, Huang F, Huang W, Lan R, Chen R, Wu B, Fu L, Yang Y, Liu J, Hong J, Zhang W, Zhang L. Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression. Front Oncol 2020;10:4. [PMID: 32117702 DOI: 10.3389/fonc.2020.00004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
558 Ge Z, Ma J, Qiao B, Wang Y, Zhang H, Gou W. Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality. Medicine (Baltimore) 2020;99:e21454. [PMID: 32769872 DOI: 10.1097/MD.0000000000021454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
559 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
560 Li J, Yang H, Yeh M, Le MH, Le AK, Yeo YH, Dai C, Barnett S, Zhang JQ, Huang J, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu M, Nguyen MH. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of Infectious Diseases 2021;224:294-302. [DOI: 10.1093/infdis/jiaa739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
561 Shi Q, Li T, Huang S, Bai Y, Wang Y, Liu J, Zhou C, Chen Y, Xiong B. Transcatheter Arterial Embolization Containing Donafenib Induces Anti-Angiogenesis and Tumoricidal CD8+ T-Cell Infiltration in Rabbit VX2 Liver Tumor. Cancer Manag Res 2021;13:6943-52. [PMID: 34522137 DOI: 10.2147/CMAR.S328294] [Reference Citation Analysis]
562 Feng H, Li B, Li Z, Wei Q, Ren L. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma. BMC Cancer 2021;21:401. [PMID: 33849479 DOI: 10.1186/s12885-021-08138-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Zhou W, Zhang Y, Zhang S, Yang Z. Absent in melanoma 1-like (AIM1L) serves as a novel candidate for overall survival in hepatocellular carcinoma. Bioengineered 2021;12:2750-62. [PMID: 34130591 DOI: 10.1080/21655979.2021.1939636] [Reference Citation Analysis]
564 Sumiya T, Mizumoto M, Oshiro Y, Baba K, Murakami M, Shimizu S, Nakamura M, Hiroshima Y, Ishida T, Iizumi T, Saito T, Numajiri H, Nakai K, Okumura T, Sakurai H. Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1840. [PMID: 32650519 DOI: 10.3390/cancers12071840] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
565 Zhao C, Xing F, Yeo YH, Jin M, Le R, Le M, Jin M, Henry L, Cheung R, Nguyen MH. Only one-third of hepatocellular carcinoma cases are diagnosed via screening or surveillance: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020;32:406-19. [PMID: 31490419 DOI: 10.1097/MEG.0000000000001523] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
566 Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC, Huang YH. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020;8:e001072. [PMID: 32863270 DOI: 10.1136/jitc-2020-001072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
567 Cunha GM, Fowler KJ, Abushamat F, Sirlin CB, Kono Y. Imaging Diagnosis of Hepatocellular Carcinoma: The Liver Imaging Reporting and Data System, Why and How? Clin Liver Dis 2020;24:623-36. [PMID: 33012449 DOI: 10.1016/j.cld.2020.07.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
568 Agnello F, Albano D, Sparacia G, Micci G, Matranga D, Toia P, La Grutta L, Grassedonio E, Lo Re G, Salvaggio G, Midiri M, Galia M. Outcome of LR-3 and LR-4 observations without arterial phase hyperenhancement at Gd-EOB-DTPA-enhanced MRI follow-up. Clin Imaging 2020;68:169-74. [PMID: 32836213 DOI: 10.1016/j.clinimag.2020.08.003] [Reference Citation Analysis]
569 Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H, Jia J, Zhuang H. A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS 2020;24:415-23. [PMID: 32522092 DOI: 10.1089/omi.2020.0055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
570 Okubo H, Ando H, Nakadera E, Ikejima K, Shiina S, Nagahara A. Levocarnitine Supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. Nutrients 2021;13:4428. [PMID: 34959980 DOI: 10.3390/nu13124428] [Reference Citation Analysis]
571 Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer 2021;21:250. [PMID: 33685409 DOI: 10.1186/s12885-021-07948-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Kokudo T, Hasegawa K. Evaluating the liver function of patients with hepatocellular carcinoma. Hepatol Res 2021;51:1095-6. [PMID: 34724293 DOI: 10.1111/hepr.13705] [Reference Citation Analysis]
573 Rim CH, Cheng J, Huang W, Kimura T, Lee V, Zeng Z, Seong J. An evaluation of hepatocellular carcinoma practice guidelines from a radiation oncology perspective. Radiotherapy and Oncology 2020;148:73-81. [DOI: 10.1016/j.radonc.2020.03.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
574 Erridge S, Sodergren MH. The Chengdu system for recurrent hepatocellular carcinoma: A step in the right direction.Hepatobiliary Surg Nutr. 2019;8:298-300. [PMID: 31245419 DOI: 10.21037/hbsn.2019.01.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
575 Wang H, Lee JC, Cao K, Tang HW, Wang S, Zhang ZY, Wu W, Yan K, Yang W. What is the difference in ablation zone of multi-bipolar radiofrequency ablation between liver cirrhosis and normal liver background? - a prospective clinical study. Int J Hyperthermia 2020;37:1248-59. [PMID: 33164634 DOI: 10.1080/02656736.2020.1838627] [Reference Citation Analysis]
576 Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. [PMID: 34914889 DOI: 10.1016/S1470-2045(21)00604-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
577 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
578 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Retrospective European Multicentric Evaluation of Selective Transarterial Chemoembolisation with and without Balloon-Occlusion in Patients with Hepatocellular Carcinoma: A Propensity Score Matched Analysis. Cardiovasc Intervent Radiol 2021;44:1048-59. [PMID: 33709273 DOI: 10.1007/s00270-021-02805-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
579 Sheng X, Ji Y, Ren GP, Lu CL, Yun JP, Chen LH, Meng B, Qu LJ, Duan GJ, Sun Q, Ye XQ, Li SS, Yang J, Liao B, Wang ZB, Zhou JH, Sun Y, Qiu XS, Wang L, Li ZS, Chen J, Xia CY, He S, Li CY, Xu EW, Geng JS, Pan C, Kuang D, Qin R, Guan HW, Wang ZD, Li LX, Zhang X, Wang H, Zhao Q, Wei B, Zhang WJ, Ling SP, Du X, Cong WM; Liver Cancer Pathology Group of China (LCPGC). A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC. Hepatol Int 2020;14:1034-47. [PMID: 33369707 DOI: 10.1007/s12072-020-10111-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
580 Zhang H, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.World J Surg Oncol. 2019;17:75. [PMID: 31039803 DOI: 10.1186/s12957-019-1619-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
581 Zhan Z, Guan Y, Mew K, Zeng W, Peng M, Hu P, Yang Y, Lu Y, Ren H. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma. Am J Physiol Gastrointest Liver Physiol 2020;318:G305-12. [PMID: 31736338 DOI: 10.1152/ajpgi.00267.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
582 Giannitrapani L, Zerbo M, Amodeo S, Pipitone E, Galia M, Li Cavoli TV, Minissale MG, Licata A, Schiavone C, Brancatelli G, Montalto G, Soresi M. The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center. Biomed Res Int 2020;2020:5309307. [PMID: 32185209 DOI: 10.1155/2020/5309307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
583 Wen N, Cai Y, Li F, Ye H, Tang W, Song P, Cheng N. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends 2022. [PMID: 35197399 DOI: 10.5582/bst.2022.01061] [Reference Citation Analysis]
584 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
585 Yuan D, Gao Z, Zhao J, Zhang H, Wang J. 125I seed implantation for hepatocellular carcinoma with portal vein tumor thrombus: A systematic review and meta-analysis. Brachytherapy 2019;18:521-9. [DOI: 10.1016/j.brachy.2019.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
586 APASL Covid-19 Task Force. Lau G, Sharma M. Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. Hepatol Int. 2020;14:415-428. [PMID: 32447721 DOI: 10.1007/s12072-020-10054-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
587 Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. [DOI: 10.1136/bmj.m3544] [Cited by in Crossref: 13] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
588 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Tang LSY, Covert E, Wilson E, Kottilil S. Chronic Hepatitis B Infection: A Review. JAMA 2018;319:1802. [DOI: 10.1001/jama.2018.3795] [Cited by in Crossref: 194] [Cited by in F6Publishing: 189] [Article Influence: 48.5] [Reference Citation Analysis]
590 D'Avola D, Bilbao JI, Sangro B. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. Cardiovasc Intervent Radiol 2019;42:1262-70. [PMID: 31069465 DOI: 10.1007/s00270-019-02221-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
591 Lee SW, Lee TY, Cheng YC, Yen CL, Yang SS. The correlation with tumor radiological characteristics and prognosis of patients with early-stage hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Medicine (Baltimore) 2021;100:e26414. [PMID: 34190159 DOI: 10.1097/MD.0000000000026414] [Reference Citation Analysis]
592 Hui RW, Chan AC, Lo G, Lo R, Chan C, Kotewall CN, Mak L, She W, Au K, Ai V, Fung J, Yuen M, Seto W. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. Hepatol Int. [DOI: 10.1007/s12072-022-10305-y] [Reference Citation Analysis]
593 Chen VL, Singal AG, Tapper EB, Parikh ND. Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver Int 2020;40:947-55. [PMID: 31943689 DOI: 10.1111/liv.14379] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
594 Sabih AH, Laube R, Strasser SI, Lim L, Cigolini M, Liu K. Palliative medicine referrals for hepatocellular carcinoma: a national survey of gastroenterologists. BMJ Support Palliat Care 2021:bmjspcare-2020-002807. [PMID: 33737287 DOI: 10.1136/bmjspcare-2020-002807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Mai RY, Zeng J, Meng WD, Lu HZ, Liang R, Lin Y, Wu GB, Li LQ, Ma L, Ye JZ, Bai T. Artificial neural network model to predict post-hepatectomy early recurrence of hepatocellular carcinoma without macroscopic vascular invasion. BMC Cancer 2021;21:283. [PMID: 33726693 DOI: 10.1186/s12885-021-07969-4] [Reference Citation Analysis]
596 Wang WJ, Xiao P, Xu HQ, Niu JQ, Gao YH. Growing burden of alcoholic liver disease in China: A review. World J Gastroenterol 2019; 25(12): 1445-1456 [PMID: 30948908 DOI: 10.3748/wjg.v25.i12.1445] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 6.3] [Reference Citation Analysis]
597 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
598 Shiina S, Sato K, Tateishi R, Shimizu M, Ohama H, Hatanaka T, Takawa M, Nagamatsu H, Imai Y. Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Can J Gastroenterol Hepatol 2018;2018:4756147. [PMID: 29974040 DOI: 10.1155/2018/4756147] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
599 Li S, Li T, Li X, Yao Y, Jiang X, Zhao L, Guo W. MicroRNA-32 Regulates Development and Progression of Hepatocellular Carcinoma by Targeting ADAMTS9 and Affects Its Prognosis. Med Sci Monit Basic Res 2018;24:177-87. [PMID: 30393368 DOI: 10.12659/MSMBR.910522] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
600 Piscaglia F, Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104-119. [PMID: 29662837 DOI: 10.1159/000485471] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 9.3] [Reference Citation Analysis]
601 Kokudo T, Hasegawa K, Shirata C, Tanimoto M, Ishizawa T, Kaneko J, Akamatsu N, Arita J, Demartines N, Uldry E, Kokudo N, Halkic N. Assessment of Preoperative Liver Function for Surgical Decision Making in Patients with Hepatocellular Carcinoma. Liver Cancer 2019;8:447-56. [PMID: 31799202 DOI: 10.1159/000501368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
602 Pan J, Tao Y, Chi X, Yang L, Zhao Y, Chen F. Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis. Eur Radiol 2022. [PMID: 35267090 DOI: 10.1007/s00330-022-08665-y] [Reference Citation Analysis]
603 An C, Lee CH, Byun JH, Lee MH, Jeong WK, Choi SH, Kim DY, Lim YS, Kim YS, Kim JH, Choi MS, Kim MJ. Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. Korean J Radiol 2019;20:1616-26. [PMID: 31854149 DOI: 10.3348/kjr.2019.0363] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
604 Saeki I, Yamasaki T, Yamashita S, Hanazono T, Urata Y, Furutani T, Yokoyama Y, Oishi T, Maeda M, Kimura T, Kotoh Y, Sasaki R, Miyaji T, Oono T, Aibe Y, Hisanaga T, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Takami T, Sakaida I. Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment. Cancers (Basel) 2020;12:E779. [PMID: 32218295 DOI: 10.3390/cancers12040779] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
605 Wang F, Numata K, Okada M, Chuma M, Nihonmatsu H, Moriya S, Nozaki A, Ogushi K, Luo W, Ruan L, Nakano M, Otani M, Inayama Y, Maeda S. Comparison of Sonazoid contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid MRI for the histological diagnosis of hepatocellular carcinoma. Quant Imaging Med Surg 2021;11:2521-40. [PMID: 34079721 DOI: 10.21037/qims-20-685] [Reference Citation Analysis]
606 Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, Xiao B, Hu Y, Qian Y, Cai T, Fu L. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal 2020;34:e23200. [PMID: 31916309 DOI: 10.1002/jcla.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
607 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
608 Jin H, Wang H, Li G, Hou Q, Wu W, Liu F. Risk factors for early postoperative recurrence in single and small hepatitis B virus-associated primary hepatocellular carcinoma. J Int Med Res 2020;48:300060520961260. [PMID: 33044114 DOI: 10.1177/0300060520961260] [Reference Citation Analysis]
609 Ko SY, Choe WH. Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization. Korean J Intern Med 2019;34:1210-1. [PMID: 31671925 DOI: 10.3904/kjim.2019.344] [Reference Citation Analysis]
610 Hsiao CY, Chen PD, Huang KW. A Prospective Assessment of the Diagnostic Value of Contrast-Enhanced Ultrasound, Dynamic Computed Tomography and Magnetic Resonance Imaging for Patients with Small Liver Tumors. J Clin Med 2019;8:E1353. [PMID: 31480576 DOI: 10.3390/jcm8091353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
611 Su C, Fang K, Lee R, Liu C, Chen P, Lee P, Kao W, Huang Y, Huo T, Hou M, Lin H, Wu J. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis. Journal of the Formosan Medical Association 2020;119:610-20. [DOI: 10.1016/j.jfma.2019.09.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
612 Wang C, Ding ZW, Zheng CG, Wang S, Li ZH, Zhang ZM, Pan J, Wang J, Yang C. COCH predicts survival and adjuvant TACE response in patients with HCC. Oncol Lett 2021;21:275. [PMID: 33732351 DOI: 10.3892/ol.2021.12536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, Kitano M, Kumada T, Izumi N, Sumino Y, Ogawa C, Akazawa K. B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial. Liver Cancer 2019;8:271-80. [PMID: 31602370 DOI: 10.1159/000501082] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
614 Huang Y, Chen X, Wang L, Wang T, Tang X, Su X. Centromere Protein F (CENPF) Serves as a Potential Prognostic Biomarker and Target for Human Hepatocellular Carcinoma. J Cancer 2021;12:2933-51. [PMID: 33854594 DOI: 10.7150/jca.52187] [Reference Citation Analysis]
615 Li G, Zhang W, Gong L, Huang X. MicroRNA 125a-5p Inhibits Cell Proliferation and Induces Apoptosis in Hepatitis B Virus-Related Hepatocellular Carcinoma by Downregulation of ErbB3. Oncol Res 2019;27:449-58. [PMID: 28800792 DOI: 10.3727/096504017X15016337254623] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
616 Zhou B, Wang J, Gao J, Xie J, Chen Y. Fidgetin as a potential prognostic biomarker for hepatocellular carcinoma. Int J Med Sci 2020;17:2888-94. [PMID: 33162817 DOI: 10.7150/ijms.49913] [Reference Citation Analysis]
617 Xie Z, Dang Y, Wu H, He R, Ma J, Peng Z, Rong M, Li Z, Yang J, Jiang Y, Chen G, Yang L. Effect of CELSR3 on the Cell Cycle and Apoptosis of Hepatocellular Carcinoma Cells. J Cancer 2020;11:2830-44. [PMID: 32226501 DOI: 10.7150/jca.39328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
618 Lim J, Kim HI, Kim E, Kim J, An J, Chang S, Kim SO, Lee HC, Lee YS, Shim JH. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study. BMC Cancer 2021;21:11. [PMID: 33402105 DOI: 10.1186/s12885-020-07708-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
619 Mai RY, Ye JZ, Long ZR, Shi XM, Bai T, Chen J, Li LQ, Wu GB, Wu FX. Preoperative aspartate aminotransferase-to-platelet-ratio index as a predictor of posthepatectomy liver failure for resectable hepatocellular carcinoma. Cancer Manag Res. 2019;11:1401-1414. [PMID: 30863151 DOI: 10.2147/cmar.s186114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
620 Kawai N, Goshima S, Noda Y, Kajita K, Kawada H, Tanahashi Y, Nagata S, Matsuo M. Gadoxetic acid-enhanced dynamic magnetic resonance imaging using optimized integrated combination of compressed sensing and parallel imaging technique. Magnetic Resonance Imaging 2019;57:111-7. [DOI: 10.1016/j.mri.2018.11.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
621 Zhang L, Jiang Z, Lv J, Liu J, Yan B, Feng Y, Li L, Zhang G, Wang F, Xu A. Comparison of hepatitis E virus seroprevalence between HBsAg-positive population and healthy controls in Shandong province, China. BMC Infect Dis 2018;18:75. [PMID: 29433428 DOI: 10.1186/s12879-018-2974-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
622 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Acute kidney injury after platinum-based transcatheter arterial chemoembolization and transarterial infusion chemotherapy in patients with hepatocellular carcinoma. Japanese Journal of Clinical Oncology 2020;50:36-43. [DOI: 10.1093/jjco/hyz129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
623 Zhang Y, Li X, Zhang Y, Wang L, Xu J, Du J, Guan Y. Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155. Ann Hepatol 2019;18:494-500. [PMID: 31036495 DOI: 10.1016/j.aohep.2018.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
624 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
625 Zhao H, Lu B. Prediction of Multiple Serum Tumor Markers in Hepatolithiasis Complicated with Intrahepatic Cholangiocarcinoma. CMAR 2022;Volume 14:249-55. [DOI: 10.2147/cmar.s344711] [Reference Citation Analysis]
626 Hamada K, Itoh T, Kawaura K, Kuno H, Kamai J, Kobayasi R, Azukisawa S, Kitakata H, Ishisaka T, Igarashi Y, Kodera K, Okuno T, Morita T, Himeno T, Yano H, Higashikawa T, Iritani O, Iwai K, Morimoto S, Matoba M, Okuro M. A Case of Refractory Esophageal Ulcer Caused by Radiotherapy for Hepatocellular Carcinoma. World J Oncol 2021;12:67-72. [PMID: 34046101 DOI: 10.14740/wjon1370] [Reference Citation Analysis]
627 Guo J, Liu S, Gao S, Kou F, Zhang X, Liu P, Yang R, Zhu X. γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. J Vasc Interv Radiol 2021;32:419-428.e2. [PMID: 33067120 DOI: 10.1016/j.jvir.2020.07.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
628 Kim NJ, Rozenberg-Ben-Dror K, Jacob DA, Rich NE, Singal AG, Aby ES, Yang JD, Nguyen V, Pillai A, Fuchs M, Moon AM, Shroff H, Agarwal PD, Perumalswami P, Chandna S, Zhou K, Patel YA, Latt NL, Wong R, Duarte-Rojo A, Lindenmeyer CC, Frenette C, Ge J, Mehta N, Yao F, Benhammou JN, Bloom PP, Leise M, Kim HS, Levy C, Barnard A, Khalili M, Ioannou GN. Provider Attitudes Toward Risk-Based Hepatocellular Carcinoma Surveillance in Patients With Cirrhosis in the United States. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31272-6. [PMID: 32927050 DOI: 10.1016/j.cgh.2020.09.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
629 Wei J, Ma L, Liu W, Wang Y, Shen C, Zhao X, Zhao C. Identification of the molecular targets and mechanisms of compound mylabris capsules for hepatocellular carcinoma treatment through network pharmacology and bioinformatics analysis. J Ethnopharmacol 2021;276:114174. [PMID: 33932512 DOI: 10.1016/j.jep.2021.114174] [Reference Citation Analysis]
630 Park SH, Kim B. Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. J Liver Cancer 2020;20:25-31. [DOI: 10.17998/jlc.20.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
631 Lee HA, Park S, Seo YS, Yoon WS, Shin I, Rim CH. Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta‐analysis. J Hepatobiliary Pancreat Sci. [DOI: 10.1002/jhbp.865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
632 Paisant A, Vilgrain V, Riou J, Oberti F, Sutter O, Laurent V, Rodes A, Guiu B, Cassinotto C, Trillaud H, Bricault I, Michalak S, Bruno O, Ronot M, Aubé C. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. Journal of Hepatology 2020;72:937-45. [DOI: 10.1016/j.jhep.2019.12.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
633 Shiha G, Waked I, Soliman R, Elbasiony M, Gomaa A, Mikhail NNH, Eslam M. GES: A validated simple score to predict the risk of HCC in patients with HCV-GT4-associated advanced liver fibrosis after oral antivirals.Liver Int. 2020;40:2828-2833. [PMID: 32946647 DOI: 10.1111/liv.14666] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
634 Li S, Lyu N, Han X, Li J, Lai J, He M, Deng H, Shi M, Wang H, Zhao M. Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. J Vasc Interv Radiol 2021;32:1267-1276.e1. [PMID: 34166806 DOI: 10.1016/j.jvir.2021.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
635 Yang CJ, Wang CK, Fang YD, Wang JY, Su FC, Tsai HM, Lin YJ, Tsai HW, Yeh LR. Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets. PLoS One 2021;16:e0255605. [PMID: 34375365 DOI: 10.1371/journal.pone.0255605] [Reference Citation Analysis]
636 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Reference Citation Analysis]
637 Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therap Adv Gastroenterol 2020;13:1756284820931734. [PMID: 32647536 DOI: 10.1177/1756284820931734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
638 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2017;6:387-396. [PMID: 29312973 DOI: 10.21037/hbsn.2017.11.01] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
639 Chen ZH, Zhang XP, Feng JK, Li LQ, Zhang F, Hu YR, Zhong CQ, Wang K, Chai ZT, Wei XB, Shi J, Guo WX, Wu MC, Lau WY, Cheng SQ. Patterns, treatments, and prognosis of tumor recurrence after resection for hepatocellular carcinoma with microvascular invasion: a multicenter study from China. HPB (Oxford) 2021:S1365-182X(21)01721-4. [PMID: 34961677 DOI: 10.1016/j.hpb.2021.11.016] [Reference Citation Analysis]
640 Lee MW, Lim HK. Management of sub-centimeter recurrent hepatocellular carcinoma after curative treatment: Current status and future. World J Gastroenterol 2018; 24(46): 5215-5222 [PMID: 30581270 DOI: 10.3748/wjg.v24.i46.5215] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
641 Navin PJ, Venkatesh SK. Hepatocellular Carcinoma: State of the Art Imaging and Recent Advances. J Clin Transl Hepatol 2019;7:72-85. [PMID: 30944823 DOI: 10.14218/JCTH.2018.00032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
642 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
643 Sukowati CHC, Cabral LKD, Tiribelli C, Pascut D. Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines 2021;9:90. [PMID: 33477833 DOI: 10.3390/biomedicines9010090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
644 Rhee H, Kim H, Park YN. Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression. Liver Cancer 2020;9:663-81. [PMID: 33442539 DOI: 10.1159/000510522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
645 Kumar A. Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma? J Hepatol 2020;73:467-8. [PMID: 32409208 DOI: 10.1016/j.jhep.2020.03.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
646 Guo JH, Liu SX, Gao S, Kou FX, Zhang X, Wu D, Li XT, Chen H, Wang XD, Liu P, Zhang PJ, Xu HF, Cao G, Zhu LZ, Yang RJ, Zhu X. Transarterial chemoembolization with hepatic arterial infusion chemotherapy plus S-1 for hepatocellular carcinoma. World J Gastroenterol 2020; 26(27): 3975-3988 [PMID: 32774071 DOI: 10.3748/wjg.v26.i27.3975] [Reference Citation Analysis]
647 Watanabe J, Endo K, Tanaka Y, Goto K, Urushibara S, Osaki T, Tatebe S, Nakamura S, Hirooka Y, Ikeguchi M. Investigation of the Utility and Safety of Dynamic Computed Tomography with Vasodilators. Yonago Acta Med 2020;63:47-54. [PMID: 32158333 DOI: 10.33160/yam.2020.02.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
648 Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
649 Duan L, Zhang BH, Liao JX, Zheng XH. Iodized oil CT-guided radiofrequency ablation for hepatocellular carcinoma within Milan criteria. Hepatol Int 2022. [PMID: 35088388 DOI: 10.1007/s12072-021-10274-8] [Reference Citation Analysis]
650 Zhuang Y, Yuan BY, Hu Y, Chen GW, Zhang L, Zhao XM, Chen YX, Zeng ZC. Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy. Cancer Manag Res 2019;11:10929-37. [PMID: 32099457 DOI: 10.2147/CMAR.S231901] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
651 Wu CC, Tseng CW, Tseng KC, Chen YC, Wu TW, Chang SY, Chang YJ, Chao YC, Hsu CS. Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: A cohort study in Taiwan. J Formos Med Assoc 2021;120:1249-58. [PMID: 33288401 DOI: 10.1016/j.jfma.2020.11.010] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
652 Purcell Y, Copin P, Paradis V, Vilgrain V, Ronot M. Lessons learnt from pathologic imaging correlation in the liver: an historical perspective. Br J Radiol 2019;92:20180701. [PMID: 30604641 DOI: 10.1259/bjr.20180701] [Reference Citation Analysis]
653 Zech CJ, Ba-Ssalamah A, Berg T, Chandarana H, Chau GY, Grazioli L, Kim MJ, Lee JM, Merkle EM, Murakami T, Ricke J, B Sirlin C, Song B, Taouli B, Yoshimitsu K, Koh DM. Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 2020;30:370-82. [PMID: 31385048 DOI: 10.1007/s00330-019-06369-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
654 Akateh C, Black SM, Conteh L, Miller ED, Noonan A, Elliott E, Pawlik TM, Tsung A, Cloyd JM. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 2019; 25(28): 3704-3721 [PMID: 31391767 DOI: 10.3748/wjg.v25.i28.3704] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 13.3] [Reference Citation Analysis]
655 Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark. 2018;23:235-242. [PMID: 30103302 DOI: 10.3233/cbm-181402] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
656 Peng C, Li C, Liu C, Wen T, Yang J, Li B, Yan L. The outcome of the HCC patients underwent ALPPS: Retrospective study. Medicine (Baltimore) 2019;98:e17182. [PMID: 31567959 DOI: 10.1097/MD.0000000000017182] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
657 Yen YH, Cheng YF, Wang JH, Lin CC, Wang CC. Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West. PLoS One 2021;16:e0244939. [PMID: 33439893 DOI: 10.1371/journal.pone.0244939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
658 Ji D, Chen GF, Niu XX, Zhang M, Wang C, Shao Q, Wu V, Wang Y, Cheng G, Hurwitz SJ, Schinazi RF, Lau G. Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study. Metabol Open 2021;10:100090. [PMID: 33889834 DOI: 10.1016/j.metop.2021.100090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
659 Laroia ST, Yadav K, Rastogi A, Kumar G, Kumar S, Sarin SK. Diagnostic efficacy of dynamic liver imaging using qualitative diagnostic algorithm versus LI-RADS v2018 lexicon for atypical versus classical HCC lesions: A decade of experience from a tertiary liver institute. Eur J Radiol Open 2020;7:100219. [PMID: 32083152 DOI: 10.1016/j.ejro.2020.100219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
660 Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-32. [PMID: 30255250 DOI: 10.1007/s00330-018-5727-1] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 10.5] [Reference Citation Analysis]
661 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
662 Ke L, Shen R, Fan W, Hu W, Shen S, Li S, Kuang M, Liang L, Li J, Peng B, Hua Y. The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. Ann Transl Med 2020;8:1402. [PMID: 33313147 DOI: 10.21037/atm-20-2420] [Reference Citation Analysis]
663 Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int. 2019;13:248-252. [PMID: 30607787 DOI: 10.1007/s12072-018-9921-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
664 Hassan I, Gane E. Improving survival in patients with hepatocellular carcinoma related to chronic hepatitis C and B but not in those related to non-alcoholic steatohepatitis or alcoholic liver disease: a 20-year experience from a national programme. Intern Med J 2019;49:1405-11. [PMID: 30908822 DOI: 10.1111/imj.14304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
665 Rim CH, Lee HY, Kim JS, Kim H. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? Int J Radiat Biol 2021;97:111-9. [PMID: 33253598 DOI: 10.1080/09553002.2021.1857453] [Reference Citation Analysis]
666 Tsai WL, Wang CF, Cheng JS, Chen WC, Bair MJ, Lo CC. Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience. PLoS One 2020;15:e0227424. [PMID: 31923251 DOI: 10.1371/journal.pone.0227424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
667 Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72:250-261. [PMID: 31954490 DOI: 10.1016/j.jhep.2019.08.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 147] [Article Influence: 131.0] [Reference Citation Analysis]
668 Choi JW, Lee JM, Lee DH, Yoon JH, Kim YJ, Lee JH, Yu SJ, Cho EJ. Radiofrequency ablation using internally cooled wet electrodes in bipolar mode for the treatment of recurrent hepatocellular carcinoma after locoregional treatment: A randomized prospective comparative study. PLoS One 2020;15:e0239733. [PMID: 32986758 DOI: 10.1371/journal.pone.0239733] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Xiang C, Xiao Y, Ma Z, Peng Y, Li X, Mao X, Li L. Liver resection for large and huge hepatocellular carcinoma: Predictors of failure, recurrence patterns, and prognoses. Asia Pac J Clin Oncol 2022. [PMID: 35404506 DOI: 10.1111/ajco.13777] [Reference Citation Analysis]
670 Heo YA, Syed YY. Regorafenib: A Review in Hepatocellular Carcinoma. Drugs 2018;78:951-8. [PMID: 29915898 DOI: 10.1007/s40265-018-0932-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
671 Han B, Ding H, Zhao S, Zhang Y, Wang J, Zhang Y, Gu J. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study. Front Oncol 2020;10:562103. [PMID: 33365268 DOI: 10.3389/fonc.2020.562103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
672 Jeon SK, Lee JM, Joo I, Yoo J, Park JY. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 2020;30:4762-71. [PMID: 32333148 DOI: 10.1007/s00330-020-06881-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
673 Fan PL, Ding H, Mao F, Chen LL, Dong Y, Wang WP. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. Eur J Radiol 2020;132:109341. [PMID: 33069987 DOI: 10.1016/j.ejrad.2020.109341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
674 Shi Q, Chen D, Zhou C, Liu J, Huang S, Yang C, Xiong B. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cancer Manag Res 2020;12:5461-8. [PMID: 32753963 DOI: 10.2147/CMAR.S255960] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
675 Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of Hepatocellular Carcinoma Surveillance and an Optimal Surveillance Interval: Nationwide Cohort of Korea. Yonsei Med J 2021;62:758-66. [PMID: 34296554 DOI: 10.3349/ymj.2021.62.8.758] [Reference Citation Analysis]
676 Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Reference Citation Analysis]
677 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
678 Colombo M, Lleo A. Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference. Transl Gastroenterol Hepatol 2018;3:104. [PMID: 30701211 DOI: 10.21037/tgh.2018.12.03] [Reference Citation Analysis]
679 Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification. Liver Cancer 2019;8:78-91. [PMID: 31019899 DOI: 10.1159/000489791] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
680 Yuan H, Li X, Tang J, Zhou M, Liu F. Local application of doxorubicin- loaded Iron oxid nanoparticles and the vascular disrupting agent via the hepatic artery: chemoembolization-photothermal ablation treatment of hepatocellular carcinoma in rats. Cancer Imaging 2019;19:71. [PMID: 31685015 DOI: 10.1186/s40644-019-0257-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
681 Takagi H, Kaji K, Nishimura N, Ishida K, Ogawa H, Takaya H, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects. Cells 2021;10:575. [PMID: 33807929 DOI: 10.3390/cells10030575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
682 Kamarajah SK, Bundred JR, Littler P, Reeves H, Manas DM, White SA. Treatment strategies for early stage hepatocellular carcinoma: a systematic review and network meta-analysis of randomised clinical trials. HPB (Oxford) 2021;23:495-505. [PMID: 33309569 DOI: 10.1016/j.hpb.2020.10.031] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
683 Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, Wongjarupong N, Ali HM, Ali HA, Hassan FA, Lavu S, Cvinar JL, Giama NH, Moser CD, Miyabe K, Allotey LK, Algeciras-Schimnich A, Theobald JP, Ward MM, Nguyen MH, Befeler AS, Reddy KR, Schwartz M, Harnois DM, Yamada H, Srivastava S, Rinaudo JA, Gores GJ, Feng Z, Marrero JA, Roberts LR. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28:531-538. [PMID: 30464023 DOI: 10.1158/1055-9965.epi-18-0281] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
684 Colombo M, Lleo A. Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients? Hepatobiliary Surg Nutr 2019;8:148-50. [PMID: 31098364 DOI: 10.21037/hbsn.2018.11.15] [Reference Citation Analysis]
685 Zhang X, Wu B, Guo Z, Gao Y, Xi W, Yu H, Feng G, Zhang J, Shen W, Chen J. Determination of portal vein tumor thrombus blood supply using in vivo cellular magnetic resonance imaging in a rabbit model. Cancer Manag Res 2019;11:5523-9. [PMID: 31417305 DOI: 10.2147/CMAR.S197231] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
686 Peng Q, Hao LY, Guo YL, Zhang ZQ, Ji JM, Xue Y, Liu YW, Lu JL, Li CG, Shi XL. Solute carrier family 2 members 1 and 2 as prognostic biomarkers in hepatocellular carcinoma associated with immune infiltration. World J Clin Cases 2022; 10(13): 3989-4019 [DOI: 10.12998/wjcc.v10.i13.3989] [Reference Citation Analysis]
687 Li Q, Zhu H. Donafenib treatment for hepatocellular carcinoma: A case report. Medicine (Baltimore) 2021;100:e26373. [PMID: 34160411 DOI: 10.1097/MD.0000000000026373] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
688 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
689 Lv K, Cao X, Du P, Fu JY, Geng DY, Zhang J. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma. World J Gastroenterol 2022; 28(20): 2176-2183 [DOI: 10.3748/wjg.v28.i20.2176] [Reference Citation Analysis]
690 Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat 2021. [PMID: 34218498 DOI: 10.1111/jvh.13569] [Reference Citation Analysis]
691 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
692 Kim PH, Choi SH, Kim JH, Park SH. Comparison of Radioembolization and Sorafenib for the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis of Safety and Efficacy. Korean J Radiol. 2019;20:385-398. [PMID: 30799569 DOI: 10.3348/kjr.2018.0496] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
693 Ogasawara S, Ooka Y, Itokawa N, Inoue M, Okabe S, Seki A, Haga Y, Obu M, Atsukawa M, Itobayashi E, Mizumoto H, Sugiura N, Azemoto R, Kanayama K, Kanzaki H, Maruta S, Maeda T, Kusakabe Y, Yokoyama M, Kobayashi K, Kiyono S, Nakamura M, Saito T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs. 2020;38:172-180. [PMID: 31172442 DOI: 10.1007/s10637-019-00801-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
694 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
695 Stocker D, Hectors S, Bane O, Vietti-Violi N, Said D, Kennedy P, Cuevas J, Cunha GM, Sirlin CB, Fowler KJ, Lewis S, Taouli B. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. Eur Radiol 2021. [PMID: 34043055 DOI: 10.1007/s00330-021-08068-5] [Reference Citation Analysis]
696 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
697 Lee HW, Cho KJ, Shin SY, Kim HY, Lee EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han K. Serum PD-1 Levels Change with Immunotherapy Response but Do Not Predict Prognosis in Patients with Hepatocellular Carcinoma. J Liver Cancer 2019;19:108-16. [DOI: 10.17998/jlc.19.2.108] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
698 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
700 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
701 Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
702 Hwang SH, Hong SB, Park S, Han K, Park YN, Kim SY, Park MS. Subcentimeter hepatocellular carcinoma in treatment-naïve patients: noninvasive diagnostic criteria and tumor staging on gadoxetic acid-enhanced MRI. Eur Radiol 2021;31:2321-31. [PMID: 33044650 DOI: 10.1007/s00330-020-07329-z] [Reference Citation Analysis]
703 Chan MV, Huo YR, Trieu N, Mitchelle A, George J, He E, Lee AU, Chang J, Yang J. Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool? Clin Gastroenterol Hepatol 2021:S1542-3565(21)00215-9. [PMID: 33662596 DOI: 10.1016/j.cgh.2021.02.036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
704 Hiraoka A, Kumada T, Michitaka K, Kudo M. Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer 2019;8:312-25. [PMID: 31768342 DOI: 10.1159/000494844] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
705 Dong Y, Zhou L, Xia W, Zhao XY, Zhang Q, Jian JM, Gao X, Wang WP. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: Initial Application of a Radiomic Algorithm Based on Grayscale Ultrasound Images. Front Oncol. 2020;10:353. [PMID: 32266138 DOI: 10.3389/fonc.2020.00353] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
706 Rhee H, Cho E, Nahm JH, Jang M, Chung YE, Baek S, Lee S, Kim M, Park M, Han DH, Choi J, Park YN. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. Journal of Hepatology 2021;74:109-21. [DOI: 10.1016/j.jhep.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
707 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
708 Wang X, Lei Y, Huan H, Chen S, Ma K, Feng K, Lau WY, Xia F. Bisegmentectomy 7-8 for Small-for-Size Remanant Liver for Cirrhotic Patients Under Right Hemi-hepatectomy With Hepatocellular Carcinoma: A Case-Matched Comparative Study. Front Surg 2021;8:675666. [PMID: 34336916 DOI: 10.3389/fsurg.2021.675666] [Reference Citation Analysis]
709 Cheng AL, Hsu C, Chan SL, Choo SP, Kudo M. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020;72:307-319. [PMID: 31954494 DOI: 10.1016/j.jhep.2019.09.025] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 69.0] [Reference Citation Analysis]
710 Coombs PR, Warsa M, Hailu T, Agedew E, Tsegaye B. Establishing an Ultrasound Screening Protocol for Chronic Liver Disease with a Handheld Device: A Pilot Project in Southern Ethiopia. Ultrasound in Medicine & Biology 2022. [DOI: 10.1016/j.ultrasmedbio.2021.12.013] [Reference Citation Analysis]
711 Ghamari SH, Yoosefi M, Abbasi-Kangevari M, Malekpour MR, Saeedi Moghaddam S, Shahin S, Esfahani Z, Koolaji S, Shobeiri P, Ghaffari A, Sohrabi H, Kazemi A, Rezaei N, Larijani B, Farzadfar F. Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019. Hepatol Commun 2022. [PMID: 35134275 DOI: 10.1002/hep4.1910] [Reference Citation Analysis]
712 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
713 Seo JY, Shin DW, Yu SJ, Jung JH, Han K, Cho IY, Kim SY, Choi KS, Park JH, Park JH, Kawachi I. Disparities in Liver Cancer Surveillance Among People With Disabilities: A National Database Study in Korea. J Clin Gastroenterol 2021;55:439-48. [PMID: 32889960 DOI: 10.1097/MCG.0000000000001405] [Reference Citation Analysis]
714 Shiina S, Gani RA, Yokosuka O, Maruyama H, Nagamatsu H, Payawal DA, Dokmeci AK, Lesmana LA, Tanwandee T, Lau G, Sarin SK, Omata M. APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatol Int. 2020;14:920-929. [PMID: 33174159 DOI: 10.1007/s12072-020-10103-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
715 Mori Y, Motosugi U, Shimizu T, Ichikawa S, Kromrey ML, Onishi H. Predicting Patients With Insufficient Liver Enhancement in the Hepatobiliary Phase Before the Injection of Gadoxetic Acid: A Practical Approach Using the Bayesian Method. J Magn Reson Imaging 2020;51:62-9. [PMID: 31016840 DOI: 10.1002/jmri.26760] [Reference Citation Analysis]
716 Chen L, Ying X, Zhang D, Lai L, Wu F, Tu J, Ji J. Iodine-125 Brachytherapy Can Prolong Progression-Free Survival of Patients with Locoregional Recurrence and/or Residual Hepatocellular Carcinoma After Radiofrequency Ablation. Cancer Biother Radiopharm 2020. [PMID: 32551979 DOI: 10.1089/cbr.2020.3647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
717 Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. Hepatol Int 2018;12:544-51. [PMID: 30426395 DOI: 10.1007/s12072-018-9908-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
718 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
719 Huang PY, Wang CC, Lin CC, Lu SN, Wang JH, Hung CH, Kee KM, Chen CH, Chen KD, Hu TH, Tsai MC. Predictive Effects of Inflammatory Scores in Patients with BCLC 0-A Hepatocellular Carcinoma after Hepatectomy. J Clin Med. 2019;8. [PMID: 31614976 DOI: 10.3390/jcm8101676] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
720 Chen YY, Chen CL, Lin CC, Wang CC, Liu YW, Li WF, Chen YH. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers (Basel) 2021;13:4584. [PMID: 34572811 DOI: 10.3390/cancers13184584] [Reference Citation Analysis]
721 Lu Y, Pan J, Zhu X, Zhang S, Liu C, Sun J, Li Y, Chen S, Huang J, Cao C, Wang Y, Li Y, Liu T. Pharmacokinetic herb-drug interactions between Aidi injection and doxorubicin in rats with diethylnitrosamine-induced hepatocellular carcinoma. BMC Pharmacol Toxicol 2021;22:48. [PMID: 34488896 DOI: 10.1186/s40360-021-00515-9] [Reference Citation Analysis]
722 Deng Z, Jin Z, Qin Y, Wei M, Wang J, Lu T, Zhang L, Zeng J, Bao L, Guo Y, Peng M, Xu B, Wen Z. Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study. World J Surg Oncol 2021;19:95. [PMID: 33785022 DOI: 10.1186/s12957-021-02199-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
723 Nakatsuka T, Tateishi R, Koike K. Changing clinical management of NAFLD in Asia. Liver Int 2021. [PMID: 34459096 DOI: 10.1111/liv.15046] [Reference Citation Analysis]
724 Wu J, Liu A, Cui J, Chen A, Song Q, Xie L. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images.BMC Med Imaging. 2019;19:23. [PMID: 30866850 DOI: 10.1186/s12880-019-0321-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
725 Tateishi R, Matsumura T, Okanoue T, Shima T, Uchino K, Fujiwara N, Senokuchi T, Kon K, Sasako T, Taniai M, Kawaguchi T, Inoue H, Watada H, Kubota N, Shimano H, Kaneko S, Hashimoto E, Watanabe S, Shiota G, Ueki K, Kashiwabara K, Matsuyama Y, Tanaka H, Kasuga M, Araki E, Koike K; LUCID study investigators. Hepatocellular carcinoma development in diabetic patients: a nationwide survey in Japan. J Gastroenterol 2021;56:261-73. [PMID: 33427937 DOI: 10.1007/s00535-020-01754-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
726 Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X. Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma. Liver Cancer 2021;10:38-51. [PMID: 33708638 DOI: 10.1159/000512028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
727 Hussain HK. Hepatobiliary-Phase Hypointense Nodules without Arterial Phase Hyperenhancement: Time to Act. Acad Radiol 2021:S1076-6332(21)00546-8. [PMID: 34922829 DOI: 10.1016/j.acra.2021.11.018] [Reference Citation Analysis]
728 Li WF, Yen YH, Liu YW, Wang CC, Yong CC, Lin CC, Cheng YF, Wang JH. Validation of an alpha-fetoprotein model to predict recurrence after liver resection for hepatocellular carcinoma. Updates Surg 2021. [PMID: 34374920 DOI: 10.1007/s13304-021-01147-8] [Reference Citation Analysis]
729 Peng Y, Liu F, Xu H, Wei Y, Li B. Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis. HPB (Oxford) 2020;22:595-602. [PMID: 31540884 DOI: 10.1016/j.hpb.2019.08.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
730 Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol. 2021;18:223-238. [PMID: 33349658 DOI: 10.1038/s41575-020-00381-6] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 24.5] [Reference Citation Analysis]
731 Maeda M, Saeki I, Sakaida I, Aikata H, Araki Y, Ogawa C, Kariyama K, Nouso K, Kitamoto M, Kobashi H, Sato S, Shibata H, Joko K, Takaki S, Takabatake H, Tsutsui A, Takaguchi K, Tomonari T, Nakamura S, Nagahara T, Hiraoka A, Matono T, Koda M, Mandai M, Mannami T, Mitsuda A, Moriya T, Yabushita K, Tani J, Yagi T, Yamasaki T. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. Liver Cancer. 2020;9:50-62. [PMID: 32071909 DOI: 10.1159/000502744] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
732 Yilma M, Saxena V, Mehta N. Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. Curr Gastroenterol Rep 2022. [PMID: 35142988 DOI: 10.1007/s11894-022-00835-8] [Reference Citation Analysis]
733 Lin H, Fan T, Sui J, Wang G, Chen J, Zhuo S, Zhang H. Recent advances in multiphoton microscopy combined with nanomaterials in the field of disease evolution and clinical applications to liver cancer. Nanoscale 2019;11:19619-35. [PMID: 31599299 DOI: 10.1039/c9nr04902a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
734 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
735 Kim T, Woo S, Han S, Suh CH, Lee DH, Lee JM. Hepatobiliary phase hypointense nodule without arterial phase hyperenhancement: are they at risk of HCC recurrence after ablation or surgery? A systematic review and meta-analysis. Eur Radiol 2020;30:1624-33. [DOI: 10.1007/s00330-019-06499-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
736 Zhong XZ, Deng Y, Chen G, Yang H. Investigation of the clinical significance and molecular mechanism of miR-21-5p in hepatocellular carcinoma: A systematic review based on 24 studies and bioinformatics investigation. Oncol Lett 2019;17:230-46. [PMID: 30655760 DOI: 10.3892/ol.2018.9627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
737 Jiang H, Song B, Qin Y, Wei Y, Konanur M, Wu Y, Zaki IH, McInnes MDF, Lafata KJ, Bashir MR. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity. J Magn Reson Imaging 2021. [PMID: 34236120 DOI: 10.1002/jmri.27824] [Reference Citation Analysis]
738 Chen W, Yang J, Fang H, Li L, Sun J. Relevance Function of Linc-ROR in the Pathogenesis of Cancer. Front Cell Dev Biol 2020;8:696. [PMID: 32850817 DOI: 10.3389/fcell.2020.00696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
739 Zhu M, Zheng J, Wu F, Kang B, Liang J, Heskia F, Zhang X, Shan Y. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol. 2020;. [PMID: 32043608 DOI: 10.1002/jmv.25704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
740 Lin CW, Chen YS, Lo GH, Hsu YC, Hsu CC, Wu TC, Yeh JH, Hsiao P, Hsieh PM, Lin HY, Shu CW, Hung CM. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. BMC Gastroenterol 2020;20:99. [PMID: 32272898 DOI: 10.1186/s12876-020-01235-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
741 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
742 Shi Q, Lu Y, Huang S, Zhou C, Yang C, Liu J, Ma J, Xiong B. Apatinib-loaded CalliSpheres Beads for embolization in a rabbit VX2 liver tumor: characterization in vitro, pharmacokinetics and tumor response in vivo. Drug Deliv 2020;27:1301-7. [PMID: 32924634 DOI: 10.1080/10717544.2020.1818881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
743 Zhang Z, Chen J, Jiang H, Wei Y, Zhang X, Cao L, Duan T, Ye Z, Yao S, Pan X, Song B. Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. Ann Transl Med 2020;8:870. [PMID: 32793714 DOI: 10.21037/atm-20-3041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
744 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications. Pharmacol Res 2022;181:106261. [PMID: 35588918 DOI: 10.1016/j.phrs.2022.106261] [Reference Citation Analysis]
745 Mai R, Lu H, Bai T, Liang R, Lin Y, Ma L, Xiang B, Wu G, Li L, Ye J. Artificial neural network model for preoperative prediction of severe liver failure after hemihepatectomy in patients with hepatocellular carcinoma. Surgery 2020;168:643-52. [DOI: 10.1016/j.surg.2020.06.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
746 Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial. Value Health Reg Issues 2021;24:82-9. [PMID: 33524900 DOI: 10.1016/j.vhri.2020.05.009] [Reference Citation Analysis]
747 Xu T, Ren L, Liao M, Zhao B, Wei R, Zhou Z, He Y, Zhang H, Chen D, Chen H, Liao W. Preoperative Radiomics Analysis of Contrast-Enhanced CT for Microvascular Invasion and Prognosis Stratification in Hepatocellular Carcinoma. JHC 2022;Volume 9:189-201. [DOI: 10.2147/jhc.s356573] [Reference Citation Analysis]
748 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]
749 Yu Q, Yin L, Jian Y, Li P, Zeng W, Zhou J. Downregulation of PHF6 Inhibits Cell Proliferation and Migration in Hepatocellular Carcinoma. Cancer Biother Radiopharm 2019;34:245-51. [PMID: 30888215 DOI: 10.1089/cbr.2018.2671] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
750 Li S, Guo JH, Lu J, Wang C, Wu H, Wang H, Zha J, Fan R. I125 irradiation stent for treatment of hepatocellular carcinoma with portal vein thrombosis: A meta-analysis. Cancer Radiother 2021;25:340-9. [PMID: 33455874 DOI: 10.1016/j.canrad.2020.12.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
751 Lin YL. Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature. World J Hepatol 2018; 10(10): 772-779 [PMID: 30386470 DOI: 10.4254/wjh.v10.i10.772] [Reference Citation Analysis]
752 Akbulut S, Garzali IU, Hargura AS, Aloun A, Yilmaz S. Screening, Surveillance, and Management of Hepatocellular Carcinoma During the COVID-19 Pandemic: a Narrative Review. J Gastrointest Canc. [DOI: 10.1007/s12029-022-00830-2] [Reference Citation Analysis]
753 Nicolosi A, Pellicano R, Caviglia GP. Surveillance of cirrhotic patients using the protein induced by vitamin K absence or antagonist II (PIVKA-II). Minerva Med 2022;113:106-8. [PMID: 35313441 DOI: 10.23736/S0026-4806.21.07952-0] [Reference Citation Analysis]
754 Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Saito T, Kobayashi K, Kiyono S, Nakamura M, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Yokosuka O, Kato N. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 2018;36:332-9. [PMID: 28891038 DOI: 10.1007/s10637-017-0507-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
755 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
756 Piñero F, Poniachik J, Ridruejo E, Silva M. Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges. World J Gastroenterol 2018; 24(37): 4224-4229 [PMID: 30310255 DOI: 10.3748/wjg.v24.i37.4224] [Cited by in CrossRef: 6] [